AFAP1 (Actin Filament-Associated Protein 1): A Comprehensive Research Report

Introduction

Actin filament-associated protein 1 (AFAP1), also known as AFAP-110 due to its apparent molecular weight of 110 kDa, is a multidomain adapter protein that plays a central role in linking signal transduction pathways to the actin cytoskeleton in human cells. The protein was first identified in the early 1990s as a major substrate of the oncogenic viral tyrosine kinase v-Src and was subsequently cloned by Flynn and colleagues [flynn-1993-afap110-identification-abstract]. The human gene encoding AFAP1 (UniProt: Q8N556) is located on chromosome 4p16.1 and produces a protein of approximately 635 amino acids. AFAP1 is the prototypical member of a family of three structurally related proteins that also includes AFAP1-like 1 (AFAP1L1) and AFAP1-like 2 (AFAP1L2, also known as XB130) [cunnick-2015-mammary-gland-abstract].

The defining characteristic of AFAP1 is its dual capacity to both bind and crosslink actin filaments while simultaneously serving as a scaffold for signaling molecules, most notably the non-receptor tyrosine kinase c-Src and protein kinase C alpha (PKCalpha). This unique combination of properties positions AFAP1 at the interface between extracellular signals and cytoskeletal reorganization, making it a key player in cellular processes including migration, adhesion, and invasion. The following sections describe the molecular architecture, biochemical functions, cellular localization, and physiological roles of this important signaling adapter.

Molecular Architecture and Domain Structure

AFAP1 is organized into a series of modular protein-binding domains that facilitate its diverse functions. The domain architecture of AFAP1 has been extensively characterized through biochemical and mutational analyses [baisden-2001-afap110-review-abstract]. The protein contains two pleckstrin homology (PH) domains located in the amino-terminal half of the protein. The first PH domain (PH1), which shows highest sequence homology to PH domains from beta-spectrin and dynamin, serves as the primary binding site for PKC family members [qian-2002-pkc-crosslinking-abstract]. The second PH domain (PH2) has been less extensively characterized but may contribute to membrane targeting through phosphoinositide binding.

Between and flanking the PH domains, AFAP1 contains two juxtaposed proline-rich SH3-binding motifs of approximately 10 amino acids each, which are essential for its interaction with the Src family kinases. These motifs engage the SH3 domain of c-Src and related kinases such as Fyn. Additionally, AFAP1 contains SH2-binding motifs with phosphotyrosine residues that, when phosphorylated, can engage the SH2 domains of Src family kinases [flynn-1993-afap110-identification-abstract]. This dual SH2/SH3 binding capacity allows AFAP1 to form stable complexes with Src under various activation states.

The carboxy-terminal region of AFAP1 contains two critical functional domains: an alpha-helical actin-binding domain and a leucine zipper motif. The actin-binding domain is both necessary and sufficient for direct association with filamentous actin (F-actin), showing approximately 40% sequence similarity with other known actin-binding motifs [qian-2000-carboxy-terminus-abstract]. The leucine zipper motif, located immediately adjacent to the actin-binding domain, mediates AFAP1 self-association and multimerization [qian-1998-src-self-association-abstract]. This multimerization is functionally significant because it allows AFAP1 to form complexes with multiple actin-binding sites, thereby enabling the protein to crosslink actin filaments.

Actin Crosslinking Function

One of the primary molecular functions of AFAP1 is its capacity to crosslink actin filaments. Biochemical studies using purified recombinant AFAP1 demonstrated that the protein binds cooperatively to actin filaments and can organize them into either loose meshwork or tight bundle structures depending on protein concentration and phosphorylation status [qian-2002-pkc-crosslinking-abstract]. The crosslinking activity depends critically on AFAP1's ability to multimerize through its leucine zipper domain, which allows the formation of complexes containing multiple actin-binding sites.

The leucine zipper motif serves a dual regulatory role in AFAP1 function. On one hand, it facilitates multimerization and thus enables actin crosslinking. On the other hand, it participates in an auto-inhibitory mechanism by making intramolecular contacts with sequences in the amino-terminal PH1 domain [qian-2004-leucine-zipper-abstract]. This auto-inhibitory configuration maintains AFAP1 in a relatively inactive conformation under basal conditions. Disruption of the leucine zipper, either through deletion mutagenesis or through phosphorylation-induced conformational changes, releases this auto-inhibition and dramatically increases the actin crosslinking capability of AFAP1. Notably, deletion of the leucine zipper motif causes AFAP1 to alter actin filament integrity and induce the formation of lamellipodia in untransformed cells, mimicking the effects of Src transformation [qian-2000-carboxy-terminus-abstract].

Size exclusion chromatography analyses have revealed that AFAP1 can exist in multiple oligomeric states in cells, ranging from monomers to tetramers in vivo and potentially higher-order multimers (up to nonamers) in vitro [qian-2004-leucine-zipper-abstract]. The transition between these oligomeric states is regulated by signaling inputs, particularly from Src and PKC.

Regulation by Protein Kinase C

AFAP1 is a direct substrate of protein kinase C alpha (PKCalpha) and this phosphorylation plays a key regulatory role in AFAP1 function. PKCalpha binds to AFAP1 through the amino-terminal PH1 domain, and this interaction results in phosphorylation of AFAP1 on serine residues [qian-2002-pkc-crosslinking-abstract]. Mutational analysis identified Ser277 as a critical PKC phosphorylation site in AFAP1. Upon treatment with phorbol esters such as phorbol 12-myristate 13-acetate (PMA) or phorbol 12,13-dibutyrate (PDBu), which activate PKC, AFAP1 becomes phosphorylated on Ser277 and undergoes conformational changes that alter its multimerization state [qian-2002-pkc-crosslinking-abstract].

PKC phosphorylation uniquely enhances the actin crosslinking ability of AFAP1. This is in marked contrast to other actin-regulatory proteins such as fascin, MARCKS, SSeCKS, and VASP, for which PKC phosphorylation decreases actin crosslinking activity. The mechanism appears to involve reduction in AFAP1 self-association, which paradoxically increases crosslinking activity, possibly by generating a population of smaller oligomers that are more effective at bridging between filaments [qian-2002-pkc-crosslinking-abstract].

Phosphorylation of Ser277 also regulates podosome dynamics. Studies in vascular smooth muscle A7r5 cells demonstrated that expression of a non-phosphorylatable AFAP1 mutant (S277A) resulted in an increased number of long-lived podosomes, suggesting that phosphorylation and dephosphorylation at this site regulate podosome turnover and stability [dorfleutner-2008-podosome-lifespan, from Journal of Cell Science 121:2394-2405]. The Ser277 site is conserved between human, chicken, rat, and mouse AFAP1, indicating evolutionary conservation of this regulatory mechanism.

Src Kinase Activation and Signaling

A defining feature of AFAP1 is its capacity to activate c-Src tyrosine kinase. AFAP1 was originally identified as an SH2/SH3 binding partner of Src, and subsequent studies have established that AFAP1 can function as an activator of Src family kinases in response to upstream signals [baisden-2001-afap110-review-abstract]. The mechanism involves phosphorylation-induced conformational changes in AFAP1 that relieve auto-inhibitory intramolecular interactions and expose the SH3-binding motifs, enabling engagement with the Src SH3 domain.

The intrinsic connection between AFAP1's ability to alter actin filament integrity and its capacity to activate tyrosine kinases was demonstrated through studies of the leucine zipper deletion mutant (AFAP1-ΔLzip) [baisden-2001-intrinsic-ability-abstract]. Unlike wild-type AFAP1, the ΔLzip mutant is capable of activating cellular tyrosine kinases, including Src family members, and is itself hyperphosphorylated on tyrosine residues. Critically, a point mutation that disrupts the SH3-binding motif of AFAP1-ΔLzip prevents it from activating tyrosine kinases and altering actin filament integrity. These findings demonstrate that conformational changes in AFAP1, whether induced by leucine zipper deletion or by physiological signals, enable it to activate cellular kinases through a mechanism requiring functional SH3-binding motifs. Furthermore, the downstream effects on actin filaments were shown to require RhoA activity, placing AFAP1-mediated Src activation upstream of Rho GTPase signaling in the cytoskeletal reorganization pathway.

The seminal study by Gatesman and colleagues demonstrated that AFAP1 is required for PKCalpha to activate c-Src and induce podosome formation [gatesman-2004-pkc-src-podosome-abstract]. In cell lines lacking AFAP1 expression, PKC activation by phorbol esters was unable to activate c-Src or induce podosome formation. Ectopic expression of wild-type AFAP1 rescued these responses, while mutant forms of AFAP1 that cannot bind or colocalize with c-Src were unable to do so. The data establish a linear signaling pathway in which PKCalpha phosphorylation of AFAP1 leads to AFAP1-mediated activation of c-Src, which in turn drives cytoskeletal reorganization and podosome formation.

Further studies identified an additional requirement for PI3K (phosphoinositide 3-kinase) signaling in this pathway [walker-2007-pi3k-csrc-abstract]. PI3K activity is required for PMA-induced colocalization between AFAP1 and c-Src and for subsequent c-Src activation. Cells lacking the p85 regulatory subunits of PI3K or treated with PI3K inhibitors showed defects in this signaling axis, resulting in impaired cell migration.

Tissue Expression and Distribution

AFAP1 exhibits broad but heterogeneous expression across human tissues. According to data from the Human Protein Atlas, AFAP1 shows ubiquitous cytoplasmic expression with a granular pattern in multiple tissues. The protein is expressed in diverse cell types including stromal cells of the endometrium, cortical neurons, peripheral nerve tissue, and over 120 other cell types and tissues. Notably, AFAP1 shows relatively high expression in peripheral blood mononuclear cells and breast tissue.

The expression pattern of AFAP1 in breast tissue is of particular interest in the context of cancer biology. While normal breast epithelial cell lines such as MCF-10A show low AFAP1 expression, and tumorigenic but less invasive breast cancer cell lines (MCF-7, T-47D, ZR-75-1) also exhibit low levels, highly invasive breast cancer cell lines MDA-MB-231 and MDA-MB-435 show markedly elevated AFAP1 expression [dorfleutner-2007-breast-cancer-abstract]. This expression pattern suggests that AFAP1 may be particularly important for the invasive phenotype rather than for proliferation per se.

AFAP1 is also expressed in ocular tissues including the retina, optic nerve, trabecular meshwork, and retinal ganglion cells [gharahkhani-2014-glaucoma-gwas-abstract]. This expression pattern has become significant in light of genome-wide association studies linking AFAP1 variants to glaucoma risk (discussed below).

Cellular Localization

AFAP1 displays a characteristic localization pattern that reflects its association with actin structures and its regulation by signaling pathways. In quiescent, untransformed cells, AFAP1 colocalizes with actin stress fibers and the cortical actin network along the cell membrane [flynn-1993-afap110-identification-abstract]. This localization depends on the carboxy-terminal actin-binding domain and positions AFAP1 to respond to signals that regulate the actin cytoskeleton.

Upon activation of PKC or transformation by Src, AFAP1 redistributes from stress fibers to specialized actin-rich adhesion structures called podosomes [gatesman-2004-pkc-src-podosome-abstract]. Podosomes are highly dynamic structures consisting of an F-actin-rich core surrounded by a ring of focal adhesion components. They are found on the ventral membrane of cells and are involved in cell adhesion and extracellular matrix degradation. AFAP1 consistently colocalizes with podosomes and has been established as a reliable molecular marker for these structures, along with cortactin and Tks5 [dorfleutner-2008-podosome-lifespan].

In cancer cells, AFAP1 also localizes to invadopodia, which are related structures that mediate invasive behavior. AFAP1 is recruited to invadopodia along with other components including Arp2/3, cortactin, and Tks5. The phosphorylation status of AFAP1 affects the dynamics of both podosomes and invadopodia, with serine phosphorylation promoting structure turnover [dorfleutner-2007-breast-cancer-abstract].

AFAP1 is also found at focal adhesions, which are larger, more stable adhesion structures that connect the actin cytoskeleton to the extracellular matrix. Studies in prostate cancer cells and breast cancer cells have demonstrated that AFAP1 is required for proper focal adhesion formation and function, with knockdown of AFAP1 resulting in disrupted focal contacts and decreased cell adhesion [zhang-2007-prostate-cancer-abstract; dorfleutner-2007-breast-cancer-abstract].

Role in Cell Adhesion and Migration

AFAP1 plays an essential role in cell adhesion and migration through its effects on the actin cytoskeleton and focal adhesion structures. Studies in MDA-MB-231 breast cancer cells demonstrated that knockdown of AFAP1 expression resulted in loss of actin stress fiber crosslinking and decreased adhesion to fibronectin [dorfleutner-2007-breast-cancer-abstract]. Although AFAP1 knockdown did not affect cell proliferation, it prevented the formation of focal contacts even when cells were treated with lysophosphatidic acid (LPA), a known stimulator of stress fiber formation and adhesion. This suggests that AFAP1 provides cytoskeletal tension through stress fiber crosslinking that is required for focal adhesion assembly.

The role of AFAP1 in cell migration was established through wound healing assays using mouse embryo fibroblasts [walker-2007-pi3k-csrc-abstract]. Cells expressing dominant-negative AFAP1 or lacking c-Src showed significantly reduced migration rates. Similarly, cells lacking the p85 regulatory subunits of PI3K showed migration defects, establishing that the PI3K-AFAP1-cSrc signaling axis is required for efficient cell migration.

In prostate cancer cells, AFAP1 knockdown reduced cell migration and invasion while disrupting focal adhesion organization [zhang-2007-prostate-cancer-abstract]. The effects were dependent on the PKC-binding capacity of AFAP1, as re-expression of wild-type AFAP1 but not a PKC-binding-deficient mutant restored normal phenotypes.

Role in Blood-Brain Barrier Function

A novel function for AFAP1 was identified in the regulation of P-glycoprotein (P-gp) activity at the blood-brain barrier [hoshi-2017-pgp-bbb-abstract]. P-glycoprotein is a critical efflux transporter that protects the brain from potentially harmful substances and affects drug delivery to the central nervous system. Using phosphoproteomic analysis in human brain capillary endothelial cells, researchers discovered that inflammatory mediators such as TNF-alpha rapidly attenuate P-gp efflux activity without changing P-gp protein expression levels. AFAP1 was identified as a key mediator of this inflammatory signaling pathway. Knockdown of AFAP1 expression blocked the TNF-alpha-induced reduction in P-gp efflux activity, establishing AFAP1 as essential for this regulatory mechanism. This finding suggests that AFAP1 plays a role in the dynamic regulation of blood-brain barrier function during inflammation, potentially through its effects on cytoskeletal organization and membrane protein function in brain endothelial cells.

Physiological Function: Lactation

A major physiological function of AFAP1 was revealed through the generation of AFAP1 knockout mice [cunnick-2015-mammary-gland-abstract]. These mice displayed a striking lactation defect resulting in inability to efficiently nurse their pups. Histological analysis of mammary glands from lactating AFAP1-null mice revealed accumulation of large cytoplasmic lipid droplets in alveolar epithelial cells, along with reduced lipid synthesis and expression of lipogenic genes. Importantly, protein secretion (as assessed by beta-casein production) was not affected, indicating a specific defect in lipid secretion rather than a general secretory failure.

The lactation defect in AFAP1-null mice was associated with reduced c-Src activity during early lactation and selective loss of active c-Src localization at the apical surface of luminal epithelial cells. AFAP1 was found to respond to prolactin, a key lactogenic hormone, by forming a complex with c-Src and becoming tyrosine phosphorylated. These findings established that AFAP1 is required for the spatial and temporal regulation of c-Src activity in the normal mammary gland, specifically for milk production [cunnick-2015-mammary-gland-abstract].

Role in Cancer

AFAP1 has been implicated in cancer progression, particularly in prostate cancer. Immunohistochemical analysis of human tissue arrays revealed that AFAP1 is absent or expressed at very low levels in normal prostatic epithelium and benign prostatic hyperplasia, but is significantly overexpressed in prostate carcinomas [zhang-2007-prostate-cancer-abstract]. The level of AFAP1 expression correlated with Gleason scores, indicating association with disease aggressiveness.

Functional studies demonstrated that knockdown of AFAP1 in prostate cancer cell lines inhibited cell proliferation, tumor growth in xenograft models, cell adhesion, and migration. Re-expression of wild-type AFAP1 rescued these phenotypes, but a mutant lacking PKC-binding capacity did not, indicating that the tumorigenic effects of AFAP1 depend on its interaction with PKC and downstream signaling [zhang-2007-prostate-cancer-abstract].

Similarly, AFAP1 is overexpressed in breast cancer cell lines MDA-MB-231 and MDA-MB-435, where it contributes to stress fiber formation and adhesion [dorfleutner-2007-breast-cancer-abstract]. The capacity of AFAP1 to activate c-Src and promote podosome/invadopodia formation suggests a role in cancer cell invasion.

A significant finding in the cancer biology of AFAP1 was the identification of a naturally occurring polymorphic variant that enhances c-Src activation [clump-2010-polymorphic-variant-abstract]. Analysis of the AFAP1 coding sequence revealed a nonsynonymous single-nucleotide polymorphism resulting in a serine-to-cysteine substitution at position 403 (S403C). This variant, designated AFAP1(403C), is present in approximately one-quarter of the general population. Importantly, in cells with elevated c-Src expression, AFAP1(403C) directs c-Src activation and podosome formation independently of upstream signals, in contrast to wild-type AFAP1 which requires PKC activation. In an analysis of ovarian cancer samples, AFAP1 and c-Src were found to be overexpressed in 30 and 32 of 33 samples, respectively. These findings suggest that individuals carrying the 403C polymorphism may be at increased risk for cancer progression when c-Src is overexpressed, providing a mechanism by which inherited genetic variation could influence cancer biology.

Genetic Association with Glaucoma

A surprising connection between AFAP1 and eye disease emerged from genome-wide association studies (GWAS) of primary open-angle glaucoma (POAG), the most common form of glaucoma and a leading cause of irreversible blindness worldwide. In a landmark study published in Nature Genetics, Gharahkhani and colleagues performed a GWAS in an Australian discovery cohort of 1,155 POAG cases and 1,992 controls, with replication in additional Australian and US cohorts [gharahkhani-2014-glaucoma-gwas-abstract]. Meta-analysis identified a common variant within the AFAP1 gene (rs4619890[G]) that conferred significantly increased risk of POAG (odds ratio = 1.20, P = 7.0 × 10^-10).

The mechanistic connection between AFAP1 and glaucoma pathophysiology remains to be fully elucidated. AFAP1 is expressed in key ocular tissues including the trabecular meshwork (which regulates aqueous humor outflow and thus intraocular pressure), the optic nerve, retina, and retinal ganglion cells (whose death underlies vision loss in glaucoma). The extracellular matrix remodeling functions suggested for AFAP1, potentially through its regulation of cytoskeletal dynamics and cell-matrix adhesions, may be relevant to trabecular meshwork function. Subsequent GWAS meta-analyses have confirmed the association of AFAP1 variants with both POAG and elevated intraocular pressure across diverse ancestral populations, establishing AFAP1 as one of the most robust genetic risk factors for this disease. Fine-mapping studies incorporating data from multiple ancestries have improved the localization of the likely causal variant at this locus.

AFAP1-AS1: An Antisense Long Non-coding RNA

An antisense long non-coding RNA (lncRNA), designated AFAP1-AS1, is transcribed from the AFAP1 locus in the opposite direction. AFAP1-AS1 has emerged as a topic of considerable research interest in cancer biology, independent of AFAP1 protein function. This lncRNA is overexpressed in multiple cancer types including gastric cancer, breast cancer, lung cancer, and others, and its elevated expression generally correlates with poor prognosis. AFAP1-AS1 functions through multiple mechanisms including sequestration of microRNAs (acting as a "sponge") and direct effects on signaling pathways involved in cancer progression. While AFAP1-AS1 can influence AFAP1 protein expression in some contexts, it also has AFAP1-independent functions. The existence of this cancer-associated lncRNA at the AFAP1 locus adds another layer of complexity to understanding the biology of this genomic region, though the functional relationship between AFAP1-AS1 and AFAP1 protein remains an area of active investigation.

The AFAP Protein Family

AFAP1 is the founding member of a three-protein family that also includes AFAP1L1 and AFAP1L2/XB130. All three proteins share a similar modular domain structure with two PH domains flanking a serine/threonine-rich region, SH2-binding motifs, and SH3-binding motifs. Cladistic analysis indicates that AFAP1 and AFAP1L1 are more closely related to each other than to AFAP1L2/XB130.

A major structural difference between the family members lies in the carboxy terminus. AFAP1 and AFAP1L1 contain a leucine zipper and actin-binding domain, enabling direct F-actin binding and crosslinking. In contrast, AFAP1L2/XB130 contains a related coiled-coil but lacks an actin-binding motif and does not bind efficiently to actin filaments. Consequently, AFAP1L2/XB130 appears to have distinct functions, acting as an intermediary between the RET/PTC kinase and PI3K pathway in the thyroid rather than primarily regulating actin dynamics.

AFAP1L1 shares many functional properties with AFAP1, including the ability to associate with actin filaments, localize to invadosomes, and induce podosomes upon overexpression. However, the tissue distribution patterns differ, with AFAP1L1 showing unique localization to muscle tissue and the dentate nucleus of the brain where AFAP1 is not detectable.

Open Questions

Despite the substantial body of research on AFAP1, several important questions remain unresolved:

1. Structural basis of function: No experimentally determined high-resolution crystal or cryo-EM structure of AFAP1 or its domains is currently available. However, an AlphaFold-predicted structure is available through the AlphaFold Protein Structure Database (entry Q8N556), which may provide insights into domain organization and the auto-inhibitory mechanism. Experimental validation of the predicted structure and its conformational dynamics would greatly enhance understanding of AFAP1 function.

2. Regulation of multimerization: While it is clear that AFAP1 exists in multiple oligomeric states and that transitions between these states are regulated, the precise structural changes and the upstream signals that control them remain incompletely defined.

3. Tissue-specific functions: The lactation defect in AFAP1 knockout mice suggests tissue-specific functions, but the roles of AFAP1 in other tissues have not been systematically investigated.

4. Relationship to metastasis: Although AFAP1 is overexpressed in prostate and breast cancers and contributes to migration and invasion, its precise contribution to metastatic dissemination in vivo remains to be determined.

5. Therapeutic targeting: Given its overexpression in certain cancers and its role in promoting tumorigenic phenotypes, AFAP1 might represent a therapeutic target, but no small-molecule inhibitors or other targeting strategies have been developed.

6. Coordination with other actin-binding proteins: How AFAP1 coordinates with other actin-binding and crosslinking proteins in cells to produce coherent cytoskeletal responses to signals is not well understood.

7. Non-canonical functions: Whether AFAP1 has signaling functions independent of its actin-binding and Src-activation roles remains an open question.

8. Mechanism of glaucoma association: The GWAS association between AFAP1 variants and primary open-angle glaucoma is robust, but the mechanistic basis for this association remains unknown. Does AFAP1 play a direct role in trabecular meshwork function, retinal ganglion cell survival, or optic nerve health? Is the risk variant a gain- or loss-of-function allele?

9. Functional consequences of the S403C polymorphism: The polymorphic variant AFAP1(403C) appears to constitutively activate c-Src, but the structural basis for this gain-of-function, and whether it contributes to cancer risk in the general population, requires further investigation.

10. Role in neuronal function: AFAP1 is expressed in neuronal tissues but its specific functions in neurons have not been characterized. Given the involvement of cytoskeletal dynamics in neuronal processes such as axon guidance and synaptic plasticity, AFAP1 may have important neurological functions.

References

• [flynn-1993-afap110-identification-abstract] Flynn DC, Leu TH, Reynolds AB, Parsons JT. Identification and sequence analysis of cDNAs encoding a 110-kilodalton actin filament-associated pp60src substrate. Mol Cell Biol. 1993;13(12):7892-7900. PMID: 8247004. DOI: 10.1128/mcb.13.12.7892-7900.1993

• [baisden-2001-afap110-review-abstract] Baisden JM, Qian Y, Zot HM, Flynn DC. The actin filament-associated protein AFAP-110 is an adaptor protein that modulates changes in actin filament integrity. Oncogene. 2001;20(44):6435-6447. PMID: 11607843. DOI: 10.1038/sj.onc.1204784

• [qian-2002-pkc-crosslinking-abstract] Qian Y, Baisden JM, Cherezova L, Summy JM, Guappone-Koay A, Shi X, Mast T, Pustula J, Zot HG, Mazloum N, Lee MY, Flynn DC. PKC phosphorylation increases the ability of AFAP-110 to cross-link actin filaments. Mol Biol Cell. 2002;13(7):2311-2322. PMID: 12134071. DOI: 10.1091/mbc.e01-12-0148

• [qian-2000-carboxy-terminus-abstract] Qian Y, Baisden JM, Zot HG, Van Winkle WB, Flynn DC. The carboxy terminus of AFAP-110 modulates direct interactions with actin filaments and regulates its ability to alter actin filament integrity and induce lamellipodia formation. Exp Cell Res. 2000;255(1):102-113. PMID: 10666339. DOI: 10.1006/excr.1999.4795

• [qian-1998-src-self-association-abstract] Qian Y, Baisden JM, Westin EH, Guappone AC, Koay TC, Flynn DC. Src can regulate carboxy terminal interactions with AFAP-110, which influence self-association, cell localization and actin filament integrity. Oncogene. 1998;16(17):2185-2195. PMID: 9619827. DOI: 10.1038/sj.onc.1201753

• [qian-2004-leucine-zipper-abstract] Qian Y, Gatesman AS, Baisden JM, Zot HG, Cherezova L, Qazi I, Mazloum N, Lee MY, Guappone-Koay A, Flynn DC. Analysis of the role of the leucine zipper motif in regulating the ability of AFAP-110 to alter actin filament integrity. J Cell Biochem. 2004;91(3):602-620. PMID: 14755689. DOI: 10.1002/jcb.10725

• [gatesman-2004-pkc-src-podosome-abstract] Gatesman A, Walker VG, Baisden JM, Weed SA, Flynn DC. Protein kinase Calpha activates c-Src and induces podosome formation via AFAP-110. Mol Cell Biol. 2004;24(17):7578-7597. PMID: 15314167. DOI: 10.1128/MCB.24.17.7578-7597.2004

• [walker-2007-pi3k-csrc-abstract] Walker VG, Ammer A, Cao Z, Clump AC, Jiang BH, Kelley LC, Weed SA, Zot H, Flynn DC. PI3K activation is required for PMA-directed activation of cSrc by AFAP-110. Am J Physiol Cell Physiol. 2007;293(1):C119-132. PMID: 17360811. DOI: 10.1152/ajpcell.00525.2006

• [zhang-2007-prostate-cancer-abstract] Zhang J, Park SI, Artime MC, Summy JM, Shah AN, Bomser JA, Dorfleutner A, Flynn DC, Gallick GE. AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts. J Clin Invest. 2007;117(10):2962-2973. PMID: 17885682. DOI: 10.1172/JCI30710

• [dorfleutner-2007-breast-cancer-abstract] Dorfleutner A, Stehlik C, Zhang J, Gallick GE, Flynn DC. AFAP-110 is required for actin stress fiber formation and cell adhesion in MDA-MB-231 breast cancer cells. J Cell Physiol. 2007;213(3):740-749. PMID: 17520695. DOI: 10.1002/jcp.21143

• [cunnick-2015-mammary-gland-abstract] Cunnick JM, Kim S, Hadsell J, Collins S, Cerra C, Reiser P, Flynn DC, Cho Y. Actin filament-associated protein 1 is required for cSrc activity and secretory activation in the lactating mammary gland. Oncogene. 2015;34(20):2640-2649. PMID: 25043309. DOI: 10.1038/onc.2014.205

• [baisden-2001-intrinsic-ability-abstract] Baisden JM, Gatesman AS, Cherezova L, Jiang BH, Flynn DC. The intrinsic ability of AFAP-110 to alter actin filament integrity is linked with its ability to also activate cellular tyrosine kinases. Oncogene. 2001;20(45):6607-6616. PMID: 11641786. DOI: 10.1038/sj.onc.1204802

• [clump-2010-polymorphic-variant-abstract] Clump DA, Yu JJ, Cho Y, Gao R, Jett J, Zot H, Cunnick JM, Snyder B, Clump AC, Dodrill M, Gannett P, Coad JE, Shurina R, Figg WD, Reed E, Flynn DC. A polymorphic variant of AFAP-110 enhances cSrc activity. Transl Oncol. 2010;3(4):276-285. PMID: 20689769. DOI: 10.1593/tlo.10106

• [gharahkhani-2014-glaucoma-gwas-abstract] Gharahkhani P, Burdon KP, Fogarty R, Sharma S, Hewitt AW, Martin S, Law MH, Cremin K, Bailey JNC, Loomis SJ, et al. Common variants near ABCA1, AFAP1 and GMDS confer risk of primary open-angle glaucoma. Nat Genet. 2014;46:1120-1125. PMID: 25173106. DOI: 10.1038/ng.3079

• [dorfleutner-2008-podosome-lifespan-abstract] Dorfleutner A, Cho Y, Vincent D, Cunnick J, Lin H, Weed SA, Stehlik C, Flynn DC. Phosphorylation of AFAP-110 affects podosome lifespan in A7r5 cells. J Cell Sci. 2008;121(14):2394-2405. PMID: 18577569. DOI: 10.1242/jcs.024943

• [hoshi-2017-pgp-bbb-abstract] Hoshi Y, Uchida Y, Tachikawa M, Ohtsuki S, Terasaki T. Actin filament-associated protein 1 (AFAP-1) is a key mediator in inflammatory signaling-induced rapid attenuation of intrinsic P-gp function in human brain capillary endothelial cells. J Neurochem. 2017;141(2):247-262. PMID: 28112407. DOI: 10.1111/jnc.13960

Citations

1. baisden-2001-afap110-review-abstract.md
2. baisden-2001-intrinsic-ability-abstract.md
3. clump-2010-polymorphic-variant-abstract.md
4. cunnick-2015-mammary-gland-abstract.md
5. dorfleutner-2007-breast-cancer-abstract.md
6. dorfleutner-2008-podosome-lifespan-abstract.md
7. flynn-1993-afap110-identification-abstract.md
8. gatesman-2004-pkc-src-podosome-abstract.md
9. gharahkhani-2014-glaucoma-gwas-abstract.md
10. hoshi-2017-pgp-bbb-abstract.md
11. qian-1998-src-self-association-abstract.md
12. qian-2000-carboxy-terminus-abstract.md
13. qian-2002-pkc-crosslinking-abstract.md
14. qian-2004-leucine-zipper-abstract.md
15. walker-2007-pi3k-csrc-abstract.md
16. zhang-2007-prostate-cancer-abstract.md

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Research plan overview
We verified AFAP1 identity, curated recent (2023–2024) primary literature, and synthesized domain architecture, mechanisms, localization, signaling pathways, physiological roles, disease links, and quantitative data where available. We prioritized human AFAP1 (AFAP-110; UniProt Q8N556) and avoided conflation with AFAP1L1/AFAP1L2 and AFAP1-AS1.

Table: Concise table summarizing AFAP1/AFAP-110 domains, mechanistic functions, localization, signaling roles, physiologic effects and recent (2023) regulatory findings with primary-source DOIs and contextual citations for each entry.

1) Key concepts and definitions with current understanding
- Identity and nomenclature. AFAP1 (actin filament-associated protein 1), also known as AFAP-110, is a human adaptor/scaffold that binds F-actin and regulates Src-family kinase signaling. It is the prototypic member of the AFAP family (AFAP1, AFAP1L1, AFAP1L2). AFAP1 is distinct from AFAP1L1 and AFAP1L2 (XB130/PI3KAP) despite sequence conservation in PH domains; AFAP1 harbors SH3-binding proline-rich motifs that engage Src, a leucine-zipper/coiled-coil for multimerization, and a C-terminal actin-binding domain that mediates actin crosslinking (snyder2011anewmember pages 26-30, snyder2011anewmember pages 30-34, qian1999monoclonalantibodiesdirected pages 1-5).
- Domain architecture. AFAP1 contains two pleckstrin homology (PH) domains (PH1 binds PKCα), multiple SH2- and SH3-binding motifs (including two N‑terminal proline-rich SH3 ligands), a central leucine-zipper/coiled-coil that mediates multimerization and conformational regulation, and a C-terminal actin-binding domain (ABD) with mapped actin-binding sequences around residues ~593–637 (qian1999monoclonalantibodiesdirected pages 1-5, xiao2012theactinbindingdomain pages 2-4, snyder2011anewmember pages 30-34).
- Primary biochemical functions. AFAP1 binds F‑actin directly and forms multimers that crosslink actin filaments; it also binds and can activate c‑Src, positioning AFAP1 as a mechanistic link between the actin cytoskeleton and Src-family kinase signaling (qian1999monoclonalantibodiesdirected pages 1-5, rubacha2010xb130insilicob pages 24-28, snyder2011anewmember pages 30-34).

2) Recent developments and latest research (2023–2024 prioritized)
- CSNK2B–IRF1 regulation of AFAP1 and antiviral signaling (2023). Matsumoto et al. demonstrated that CSNK2B (CK2β) interacts with IRF1 to modulate genome-wide chromatin binding; CSNK2B depletion causes an abnormal accumulation of IRF1 at AFAP1 loci and downregulates AFAP1 transcription. CSNK2B further mediates phosphorylation-dependent activation of AFAP1–Src signaling and contributes to antiviral effects against flaviviruses, identifying AFAP1 as an IRF1/CK2β‑responsive effector that connects cytoskeletal signaling to innate immunity (Nucleic Acids Research, 2023; doi:10.1093/nar/gkad298) (matsumoto2023csnk2bmodulatesirf1 pages 1-2).
- Context from established AFAP1 mechanistic literature supports and frames the 2023 finding: AFAP1’s ability to activate Src and remodel actin provides biological plausibility for antiviral phenotypes when AFAP1–Src signaling is modulated (snyder2011anewmember pages 30-34, rubacha2010xb130insilicob pages 24-28, xiao2012theactinbindingdomain pages 1-2).

3) Current applications and real-world implementations
- Physiological model and in vivo application (mammary gland). AFAP1 knockout in mice revealed a requirement for AFAP1 in secretory activation during lactation: AFAP1 forms a prolactin-induced complex with c‑Src, becomes tyrosine‑phosphorylated, and is necessary for spatial and temporal regulation of c‑Src activity at the apical surface of luminal epithelial cells; AFAP1 loss reduces c‑Src activity and impairs milk production (Oncogene, 2015; doi:10.1038/onc.2014.205) (cunnick2015actinfilamentassociatedprotein pages 1-3).
- Cell biology tools/assays. AFAP1 domain mutants (ΔABD, Δleucine zipper) are used to dissect actin-binding vs. multimerization functions, assess stress fiber formation, focal adhesion maturation, podosome/invadopodia dynamics, and matrix degradation in multiple cell models; these reagents are widely used to probe cytoskeletal signaling and Src activation in vitro (Cell Mol Life Sci, 2012; doi:10.1007/s00018-011-0812-5) (xiao2012theactinbindingdomain pages 2-4).
- Emerging virology application. The 2023 IRF1–CSNK2B study links AFAP1 to host antiviral responses, suggesting AFAP1–Src signaling as a cellular effector that can be leveraged or modulated in antiviral strategies (Nucleic Acids Research, 2023; doi:10.1093/nar/gkad298) (matsumoto2023csnk2bmodulatesirf1 pages 1-2).

4) Expert opinions and analysis from authoritative sources
- AFAP1 as Src activator and actin crosslinker. Foundational analyses describe AFAP1 as a c‑Src activator and actin crosslinking protein that is essential for stress fiber formation and focal adhesion maturation, and that re-localizes to podosomes/invadopodia upon transformation or PKC activation. These mechanistic insights underpin consensus views of AFAP1 as a cytoskeleton–Src adaptor (thesis and review-style syntheses with primary data and citations) (snyder2011anewmember pages 30-34, snyder2011anewmember pages 39-43).
- Domain-function relationships. Detailed mapping shows that PH1 mediates PKCα interaction and phosphorylation (e.g., Ser277), the leucine-zipper/coiled-coil supports multimerization and autoinhibitory contacts, and the C‑terminal ABD is necessary for stable F‑actin association—consistent with an autoinhibited scaffold that is activated by PKC and engages Src (snyder2011anewmember pages 30-34, qian1999monoclonalantibodiesdirected pages 1-5, xiao2012theactinbindingdomain pages 2-4).

5) Relevant statistics and data from recent studies
- 2023 IRF1–CSNK2B study. Genome-wide CUT&RUN and functional assays showed that CSNK2B depletion produces locus-specific shifts in IRF1 binding with down-regulation of AFAP1 and phosphorylation-dependent activation of AFAP1–Src signaling, contributing to antiviral responses; while the study highlights mechanistic outcomes and specific loci, quantitative parameters most relevant here are the directional regulatory effects at AFAP1 and the functional linkage to antiviral phenotypes (Nucleic Acids Research, 2023; doi:10.1093/nar/gkad298) (matsumoto2023csnk2bmodulatesirf1 pages 1-2).
- In vivo lactation phenotype. AFAP1-null mice demonstrated reduced c‑Src activity during early lactation and loss of apical active c‑Src localization; histology showed large cytoplasmic lipid droplets in alveolar epithelia indicating defective secretory activation (Oncogene, 2015; doi:10.1038/onc.2014.205) (cunnick2015actinfilamentassociatedprotein pages 1-3).
- Actin-binding requirement. Deletion of the ABD shifts AFAP1 from the Triton-insoluble cytoskeletal fraction to the soluble fraction, with concomitant disruption of stress fibers and altered matrix degradation in podosome-like structures, indicating a quantitative redistribution of AFAP1 upon loss of ABD and a functional dependence of cytoskeletal association on the ABD (Cell Mol Life Sci, 2012; doi:10.1007/s00018-011-0812-5) (xiao2012theactinbindingdomain pages 2-4).

Functional role, pathways, and localization
- Primary function. AFAP1 is a modular actin-binding adaptor that crosslinks F‑actin via multimerization and couples cytoskeletal dynamics to Src-family kinase activation. It binds c‑Src through proline-rich SH3 ligands and SH2 motifs and can increase Src activity; PKCα phosphorylates AFAP1 (PH1 interaction), transitioning AFAP1 from an autoinhibited state to an active scaffold that promotes Src activation and cytoskeletal remodeling (qian1999monoclonalantibodiesdirected pages 1-5, snyder2011anewmember pages 30-34, rubacha2010xb130insilicob pages 24-28).
- Localization. AFAP1 localizes to stress fibers and focal adhesions under basal conditions. Upon PKC/Src activation or oncogenic transformation, AFAP1 relocates to podosomes/invadopodia and lamellipodia; in mammary epithelium, AFAP1 is required for the apical localization of active Src during lactation (xiao2012theactinbindingdomain pages 2-4, cunnick2015actinfilamentassociatedprotein pages 1-3, snyder2011anewmember pages 30-34).
- Pathways. Key axes include PKC→AFAP1→Src (PKCα binding to PH1 and Ser277 phosphorylation facilitate Src activation and podosome formation) and TGF‑β→AFAP1→Src→CCN2 induction in osteoblasts (AFAP1 required for Src activation and CCN2 promoter activity in response to TGF‑β) (snyder2011anewmember pages 30-34, cunnick2015actinfilamentassociatedprotein pages 1-3).

Disease and translational relevance
- Cancer cell invasion and adhesion. AFAP1 supports stress fiber formation, focal adhesion maturation, and invadopodia/podosome dynamics. RNAi or loss-of-function reduces adhesion/migration/invasion phenotypes in breast and prostate cancer models, and AFAP1 upregulation has been reported in certain tumors, consistent with a role in invasive behavior (snyder2011anewmember pages 30-34, snyder2011anewmember pages 39-43, rubacha2010xb130insilicob pages 24-28).
- Host defense. 2023 data integrate AFAP1 into IRF1/CK2β‑controlled antiviral signaling, linking a cytoskeletal–Src adaptor to innate immune regulation and suggesting potential for therapeutic modulation (matsumoto2023csnk2bmodulatesirf1 pages 1-2).

Mandatory verification of identity
- Gene symbol and protein description match: AFAP1 encodes actin filament-associated protein 1 (AFAP‑110), as specified; features and functions summarized above align with this identity (qian1999monoclonalantibodiesdirected pages 1-5, xiao2012theactinbindingdomain pages 2-4).
- Organism is human: all core mechanistic evidence cited includes human protein context and mammalian models, consistent with Homo sapiens AFAP1 (qian1999monoclonalantibodiesdirected pages 1-5, xiao2012theactinbindingdomain pages 2-4, cunnick2015actinfilamentassociatedprotein pages 1-3).
- Domains/family alignment: two PH domains, SH3-binding proline-rich motifs, SH2-binding motifs, leucine-zipper/coiled-coil, and C‑terminal ABD are repeatedly validated in the literature for AFAP1 (qian1999monoclonalantibodiesdirected pages 1-5, xiao2012theactinbindingdomain pages 2-4, snyder2011anewmember pages 30-34). We explicitly avoid conflation with AFAP1L1 (cortactin‑interacting) and AFAP1L2/XB130 (PI3KAP), which have overlapping but distinct C‑terminal features (snyder2011anewmember pages 26-30, snyder2011anewmember pages 39-43).

Notes on AFAP1-AS1
- The lncRNA AFAP1‑AS1 is frequently studied in cancer and shows disease associations; however, those statistics and mechanisms correspond to the antisense noncoding RNA, not the AFAP1 protein, and are therefore not used here to infer AFAP1 protein function (xiao2012theactinbindingdomain pages 1-2).

Selected source details with URLs and dates
- Matsumoto et al., 2023, Nucleic Acids Research 51:4451–4466. CSNK2B–IRF1 regulation of AFAP1, antiviral effects; doi:10.1093/nar/gkad298; published April 2023 (matsumoto2023csnk2bmodulatesirf1 pages 1-2).
- Cunnick et al., 2015, Oncogene 34:2640–2649. AFAP1 knockout mouse reveals role in lactation and c‑Src activity/localization; doi:10.1038/onc.2014.205; online May 14, 2015 (cunnick2015actinfilamentassociatedprotein pages 1-3).
- Xiao et al., 2012, Cell Mol Life Sci 69:1137–1151. AFAP ABD requirement for cytoskeletal association and podosome-related function; doi:10.1007/s00018-011-0812-5; October 2012 (xiao2012theactinbindingdomain pages 2-4).
- Qian et al., 1999, Hybridoma 18:167–175. AFAP-110 domain mapping, multimerization, actin binding; doi:10.1089/hyb.1999.18.167; April 1999 (qian1999monoclonalantibodiesdirected pages 1-5).
- Mechanistic syntheses with primary data: Snyder, 2011 (AFAP1 domains, Src activation, PKC regulation, family distinctions), ArXiv DOI 10.33915/etd.3379; 2011 (snyder2011anewmember pages 26-30, snyder2011anewmember pages 30-34, snyder2011anewmember pages 39-43).

Conclusion
Human AFAP1 (AFAP‑110; Q8N556) is a modular adaptor that crosslinks actin and directly regulates Src-family kinase signaling through SH3/SH2 interactions and PKC‑dependent conformational control. It localizes to stress fibers and focal adhesions but redistributes to podosomes/invadopodia under PKC/Src activation, and it is essential for spatial c‑Src activation in lactating mammary epithelium. New 2023 data place AFAP1 under IRF1/CK2β transcriptional and post‑translational control with consequences for antiviral responses, extending AFAP1’s relevance beyond cancer cell motility into innate immunity (qian1999monoclonalantibodiesdirected pages 1-5, xiao2012theactinbindingdomain pages 2-4, cunnick2015actinfilamentassociatedprotein pages 1-3, snyder2011anewmember pages 30-34, matsumoto2023csnk2bmodulatesirf1 pages 1-2).

References

1. (snyder2011anewmember pages 26-30): Brandi Nicole Snyder. A new member of the afap family, afap1l1, binds to cortactin and localizes to invadosomes. ArXiv, 2011. URL: https://doi.org/10.33915/etd.3379, doi:10.33915/etd.3379. This article has 0 citations.

2. (snyder2011anewmember pages 30-34): Brandi Nicole Snyder. A new member of the afap family, afap1l1, binds to cortactin and localizes to invadosomes. ArXiv, 2011. URL: https://doi.org/10.33915/etd.3379, doi:10.33915/etd.3379. This article has 0 citations.

3. (qian1999monoclonalantibodiesdirected pages 1-5): YONG QIAN, ANNE C. GUAPPONE, JOSEPH M. BAISDEN, M. WYNN HILL, JUSTIN M. SUMMY, and DANIEL C. FLYNN. Monoclonal antibodies directed against afap-110 recognize species-specific and conserved epitopes. Hybridoma, 18 2:167-75, Apr 1999. URL: https://doi.org/10.1089/hyb.1999.18.167, doi:10.1089/hyb.1999.18.167. This article has 16 citations.

4. (xiao2012theactinbindingdomain pages 2-4): Helan Xiao, Bing Han, Monika Lodyga, Xiao-Hui Bai, Yingchun Wang, and Mingyao Liu. The actin-binding domain of actin filament-associated protein (afap) is involved in the regulation of cytoskeletal structure. Cellular and Molecular Life Sciences, 69:1137-1151, Oct 2012. URL: https://doi.org/10.1007/s00018-011-0812-5, doi:10.1007/s00018-011-0812-5. This article has 15 citations and is from a domain leading peer-reviewed journal.

5. (rubacha2010xb130insilicob pages 24-28): M Rubacha. Xb130: in silico and invivo studies of a novel signal adaptor protein. Unknown journal, 2010.

6. (cunnick2015actinfilamentassociatedprotein pages 1-3): J. Cunnick, Stephanie Kim, J. Hadsell, S. Collins, C. Cerra, P. Reiser, D. Flynn, and Y. Cho. Actin filament-associated protein 1 is required for csrc activity and secretory activation in the lactating mammary gland. Oncogene, 34:2640-2649, Jul 2015. URL: https://doi.org/10.1038/onc.2014.205, doi:10.1038/onc.2014.205. This article has 16 citations and is from a domain leading peer-reviewed journal.

7. (matsumoto2023csnk2bmodulatesirf1 pages 1-2): Moe Matsumoto, Jennifer L Modliszewski, Kotomi Shinozaki, Reona Maezawa, Vincent M Perez, Yuki Ishikawa, Ryosuke Suzuki, Kevin L McKnight, Takahiro Masaki, Asuka Hirai-Yuki, Michinori Kohara, Stanley M Lemon, Sara R Selitsky, and Daisuke Yamane. Csnk2b modulates irf1 binding to functional dna elements and promotes basal and agonist-induced antiviral signaling. Nucleic Acids Research, 51:4451-4466, Apr 2023. URL: https://doi.org/10.1093/nar/gkad298, doi:10.1093/nar/gkad298. This article has 5 citations and is from a highest quality peer-reviewed journal.

8. (snyder2011anewmember pages 39-43): Brandi Nicole Snyder. A new member of the afap family, afap1l1, binds to cortactin and localizes to invadosomes. ArXiv, 2011. URL: https://doi.org/10.33915/etd.3379, doi:10.33915/etd.3379. This article has 0 citations.

9. (xiao2012theactinbindingdomain pages 1-2): Helan Xiao, Bing Han, Monika Lodyga, Xiao-Hui Bai, Yingchun Wang, and Mingyao Liu. The actin-binding domain of actin filament-associated protein (afap) is involved in the regulation of cytoskeletal structure. Cellular and Molecular Life Sciences, 69:1137-1151, Oct 2012. URL: https://doi.org/10.1007/s00018-011-0812-5, doi:10.1007/s00018-011-0812-5. This article has 15 citations and is from a domain leading peer-reviewed journal.

Citations

1. cunnick2015actinfilamentassociatedprotein pages 1-3
2. xiao2012theactinbindingdomain pages 2-4
3. xiao2012theactinbindingdomain pages 1-2
4. qian1999monoclonalantibodiesdirected pages 1-5
5. snyder2011anewmember pages 26-30
6. snyder2011anewmember pages 30-34
7. snyder2011anewmember pages 39-43
8. https://doi.org/10.33915/etd.3379
9. https://doi.org/10.1089/hyb.1999.18.167
10. https://doi.org/10.1007/s00018-011-0812-5
11. https://doi.org/10.1038/onc.2014.205
12. https://doi.org/10.1093/nar/gkad298
13. https://doi.org/10.33915/etd.3379,
14. https://doi.org/10.1089/hyb.1999.18.167,
15. https://doi.org/10.1007/s00018-011-0812-5,
16. https://doi.org/10.1038/onc.2014.205,
17. https://doi.org/10.1093/nar/gkad298,

Introduction and Gene Identification

Actin Filament-Associated Protein 1 (AFAP1, a.k.a. AFAP-110) is a human protein encoded by the AFAP1 gene (UniProt Q8N556) (www.ncbi.nlm.nih.gov). The gene symbol AFAP1 refers specifically to the human actin filament-associated protein 1, not to be confused with similarly named genes or transcripts in other contexts. AFAP1 was originally identified as a 110 kDa protein associated with actin filaments and as a binding partner of the Src family tyrosine kinase (www.nature.com). It is now recognized as a multi-domain adaptor protein that links signaling molecules to the actin cytoskeleton and modulates actin filament organization (www.nature.com). AFAP1 is expressed in a wide range of human tissues (low tissue specificity) and is localized intracellularly, particularly along actin filaments and at focal adhesion sites (v19.proteinatlas.org). In cell imaging, AFAP1 shows a cytosolic, granular pattern and co-localizes with actin structures including stress fibers and focal adhesions (v19.proteinatlas.org). This widespread expression suggests a general role in cytoskeletal regulation across cell types. Consistent with this, high AFAP1 levels have been observed in certain cell types (e.g. eosinophils) and tissues, indicating potential cell-specific functions in the immune and other systems (v19.proteinatlas.org) (v19.proteinatlas.org).

Protein Structure and Domains: AFAP1 is a modular protein comprising several conserved domains that underpin its function. Notably, AFAP1 contains two Pleckstrin Homology (PH) domains, an N-terminal proline-rich motif that binds SH3 domains, multiple SH2-binding motifs (tyrosine-based motifs that can bind SH2 domains when phosphorylated), a central Serine/Threonine-rich segment (substrate domain) targeted by protein kinase C (PKC), a leucine zipper motif, and a C-terminal actin-binding domain (www.nature.com) (pmc.ncbi.nlm.nih.gov). The two PH domains (often termed PH1 and PH2) suggest the protein can associate with membrane lipids or PH-domain binding proteins, and indeed PH1 at the N-terminus is implicated in binding to PKC and possibly targeting AFAP1 to specific subcellular sites (pmc.ncbi.nlm.nih.gov). The leucine zipper (LZ) near the C-terminus mediates AFAP1 self-multimerization (dimerization/oligomerization) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This multimerization, together with the actin-binding domains on each AFAP1 molecule, allows AFAP1 to function as an actin cross-linking protein, bridging actin filaments into networks or bundles (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Structural studies show that AFAP1’s LZ-driven multimer can present multiple actin-binding sites, enabling it to organize actin filaments into either loose meshworks or tightly bundled arrays depending on context (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The protein’s autoinhibitory interactions are also tied to its domain structure: in the resting state, an intramolecular contact between the N-terminal PH1 domain and the C-terminal leucine zipper keeps AFAP1 in a closed/inhibited conformation (pmc.ncbi.nlm.nih.gov). This masks its actin-crosslinking and signaling functions until appropriate signals are received. For instance, a specific single-nucleotide polymorphism (S403C) located in the second PH domain disrupts AFAP1’s normal intramolecular interactions and promotes a more open conformation, as discussed later (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In summary, AFAP1’s domain architecture is central to its function as a regulated adaptor: the PH domains and proline motifs mediate lipid and protein interactions, the leucine zipper and actin-binding domain enable scaffold formation on actin filaments, and multiple phosphorylation sites allow signal-dependent modulation of its activity (www.nature.com) (pmc.ncbi.nlm.nih.gov).

Actin Binding and Cytoskeletal Modulation

AFAP1 is classified functionally as an actin-binding and cross-linking protein that can directly bind filamentous actin (F-actin) and influence the architecture of the actin cytoskeleton (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The C-terminal ~100 amino acids of AFAP1 constitute a defined actin-binding domain that attaches to actin filaments (www.nature.com). Through its leucine zipper-driven self-association, AFAP1 can form dimers or higher-order oligomers, effectively linking actin filaments to each other. Biochemical and cell-based assays have shown that AFAP1 can organize actin filaments into different configurations: at lower concentrations or specific phosphorylation states it tends to induce looser networks, whereas under other conditions it promotes tight filament bundles (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This dynamic reflects AFAP1’s role as a cytoskeletal modulator – it is not a passive structural component, but rather an active organizer of actin filament integrity. Indeed, AFAP1 can both stabilize and remodel actin structures in response to signals. For example, in vitro experiments demonstrated that AFAP1 can cross-link actin filaments, and that this activity is enhanced by PKC-mediated phosphorylation (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Protein kinase C (PKC) phosphorylates AFAP1 on its serine/threonine-rich region, and this has been shown to increase AFAP1’s actin-bundling ability (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Mechanistically, PKC phosphorylation is thought to relieve AFAP1’s autoinhibition (possibly by disrupting the PH1–leucine zipper intramolecular clamp), allowing AFAP1 to multimerize and bind actin more effectively (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). A 2002 cell biology study reported that PKC-dependent phosphorylation of AFAP1 significantly boosted its capacity to cross-link actin filaments, correlating with the formation of robust actin structures in cells (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

Importantly, AFAP1’s actin-modulating function is not constitutive but is regulated by upstream signals and possibly by its own conformational state. Under basal conditions, AFAP1 appears to contribute to maintaining actin cytoskeletal support structures such as stress fibers. In highly motile breast cancer cells (MDA-MB-231), for instance, AFAP1 is required for normal stress fiber formation and actin filament cross-linking (www.scholars.northwestern.edu) (www.scholars.northwestern.edu). Knockdown of AFAP1 in these cells led to a loss of actin stress fibers and reduced actin filament cross-linking, indicating that AFAP1 is necessary to generate the tension-bearing bundled actin architecture (www.scholars.northwestern.edu) (www.scholars.northwestern.edu). Without AFAP1, the cells also showed decreased adhesion to the extracellular matrix (fibronectin) and an inability to form mature focal adhesions (www.scholars.northwestern.edu) (www.scholars.northwestern.edu). Conversely, in the presence of AFAP1, cells can form robust stress fibers that transmit contractile forces to focal adhesions, promoting strong adhesion to the substrate (www.scholars.northwestern.edu) (www.scholars.northwestern.edu). Researchers concluded that AFAP1 helps provide cytoskeletal tension through cross-linked stress fibers, which is required to stabilize focal adhesion complexes (www.scholars.northwestern.edu) (www.scholars.northwestern.edu). This explains why AFAP1-deficient cells failed to assemble focal adhesions despite normal levels of integrins and other adhesion proteins – the actin framework needed to cluster and reinforce those adhesions was missing (www.scholars.northwestern.edu) (www.scholars.northwestern.edu).

In addition to supporting stable actin bundles, AFAP1 is also involved in the formation of dynamic actin structures like lamellipodia and podosomes under the right conditions. Studies have shown that upon certain stimuli, AFAP1 can induce actin reorganization into punctate, actin-rich structures called podosomes (or invadopodia in cancer cells) (www.nature.com) (www.nature.com). Podosomes are adhesive, actin-core structures associated with extracellular matrix degradation and cell invasion. In vascular smooth muscle cells and other cell models, activation of PKC (for example by phorbol esters) triggers rapid podosome formation, a process in which AFAP1 is a critical mediator (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). AFAP1 responds to PKC signals by altering actin filament integrity – essentially breaking down parts of stress fibers and repurposing actin into podosome cores (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). A 2004 molecular biology study by Gatesman et al. demonstrated that PKCα activates c-Src and induces podosome formation via AFAP-110 (AFAP1) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In that pathway, AFAP1 serves as a hub where PKC signals converge to locally rearrange actin and activate Src (discussed below). Notably, phosphorylation of AFAP1 has been shown to affect podosome dynamics – one report found that specific phosphorylation sites on AFAP1 control the lifespan of podosomes, influencing how long these structures persist in cells (www.nature.com). Thus, AFAP1 is instrumental in the formation and regulation of specialized invasive actin structures. Moreover, AFAP1 can also promote lamellipodia formation (broad, sheet-like actin protrusions) when its conformation is altered. Early experiments noted that certain mutations or C-terminal truncations of AFAP1 unleashed its ability to induce lamellipodia and membrane ruffles (www.nature.com). In summary, AFAP1 acts as an actin cytoskeletal regulator with a dual nature – it can stabilize actin filament bundles to support adhesion, or it can facilitate actin remodeling into structures that drive cell migration and invasion, depending on the signaling context (www.nature.com) (www.nature.com).

Adaptor Role in Src Signaling

One of AFAP1’s defining functions is serving as an adaptor protein linking signaling molecules (especially Src-family tyrosine kinases) to the actin cytoskeleton (www.ncbi.nlm.nih.gov) (www.nature.com). AFAP1 was first discovered as a binding partner and substrate of the viral Src oncoprotein (v-Src) (pmc.ncbi.nlm.nih.gov), and later work confirmed it binds the cellular Src (c-Src) and related Src-family kinases. AFAP1 contains an SH3-binding motif (PXXP) near its N-terminus that can directly bind the SH3 domain of Src (pubmed.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov). This interaction tethers Src in proximity to actin filaments. AFAP1 also has multiple tyrosine residues that, when phosphorylated (for instance by Src itself), create SH2-binding sites. This means AFAP1 can form a tight complex with Src by engaging both the SH3 and SH2 domains of Src (the latter upon AFAP1’s phosphorylation) (www.nature.com) (www.nature.com). Indeed, mutational studies showed that disrupting AFAP1’s SH3-binding proline motif abrogates its association with Src (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov), and conversely, phosphorylation at certain YXXP motifs stabilizes the Src–AFAP1 complex (www.nature.com). Through these interactions, AFAP1 acts as a scaffold that recruits Src to actin filaments and focal adhesion sites. Functionally, this scaffolding is significant because c-Src’s activity and localization need tight regulation – c-Src in solution is auto-inhibited, but when brought to specific sites (e.g. the cell membrane or adhesions) and released from autoinhibition, it can phosphorylate targets to drive signaling pathways (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). AFAP1 has emerged as a key “Src-activating protein” that can trigger c-Src’s kinase activity in response to upstream signals (pmc.ncbi.nlm.nih.gov).

Activation of Src: Normally, c-Src is kept in a closed, inactive conformation. AFAP1 can promote Src activation by inducing a conformational change that “frees” Src from its autoinhibited state (pmc.ncbi.nlm.nih.gov). In cells stimulated with PKC or growth factors, AFAP1 is believed to undergo a conformational opening (as described earlier) and multimerize, which not only enhances actin binding but also allows AFAP1’s Src-binding motifs to engage Src more effectively (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). By binding Src’s SH3 domain, AFAP1 competes with Src’s own intramolecular SH3–linker interaction, and thus disrupts Src’s autoinhibition (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Once Src is docked on AFAP1 and released, it may phosphorylate AFAP1 further (creating SH2 docking sites), leading to a stable Src–AFAP1 complex (www.nature.com) (www.nature.com). Crucially, AFAP1-mediated Src activation has been observed in several experimental systems. For example, Clump et al. (2010) found that an inherited variant of AFAP1 (Ser403Cys) caused constitutive Src activation in cells with high Src levels (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The variant AFAP1^403C could drive Src to form active signaling structures (podosomes) without any external PKC signal, whereas wild-type AFAP1 required upstream signals to do so (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This underscores AFAP1’s normal role as a signal-responsive Src activator. Under physiological conditions, PKCα is a major upstream signal that works through AFAP1 to activate Src (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). PKC can bind AFAP1 (via the PH1 domain) and phosphorylate it (pmc.ncbi.nlm.nih.gov). Activated PKCα was shown to trigger c-Src activation and downstream podosome formation via AFAP1, meaning if AFAP1 is absent or mutated, PKC fails to fully activate Src (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Additional signaling crosstalk is involved as well – PI3K activity is required for PKC/Afap1 to activate Src, hinting that lipid products (e.g. PIP₃) or PI3K-dependent proteins (like RACK1) cooperate in this pathway (pmc.ncbi.nlm.nih.gov). AFAP1’s PH domains may bind phosphoinositides at the membrane or partner with RACK1 (Receptor for Activated C Kinase, a WD40-repeat scaffolding protein) (pmc.ncbi.nlm.nih.gov). In fact, it’s suggested that AFAP1’s PH domains help localize the PKC–AFAP–Src complex to membrane or adhesion sites, where RACK1 and lipids provide a platform (pmc.ncbi.nlm.nih.gov). Through such mechanisms, AFAP1 positions active Src in specific subcellular locales (such as focal adhesions, membrane ruffles, or podosomes) to phosphorylate target proteins and propagate signals (pmc.ncbi.nlm.nih.gov) (www.nature.com).

Biological Signaling Pathways: By linking Src to actin, AFAP1 influences multiple signal transduction pathways related to cytoskeletal dynamics and cell adhesion. Once activated by AFAP1, Src kinase can phosphorylate focal adhesion components (e.g. FAK, paxillin) and actin regulators, leading to changes in cell migration and adhesion signaling. AFAP1 thereby affects cell–ECM interaction pathways: if actin filaments are not properly organized (as in AFAP1 knockdown), focal adhesion signaling (integrin/Src/FAK signaling) is impaired (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In contrast, AFAP1’s ability to recruit Src to adhesion sites can enhance integrin-mediated signaling and focal contact turnover, facilitating dynamic movement. It is notable that AFAP1 can serve as a platform for “larger signaling complexes” (www.nature.com) – for example, an AFAP1 multimer might bring together Src, PKC, and actin filaments all in one locale, allowing crosstalk between tyrosine kinase and PKC pathways. AFAP1 has also been reported to bind other signaling or structural proteins: while AFAP1 itself does not efficiently bind cortactin (another actin-binding scaffold) (pubmed.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov), its homologs do, indicating AFAP1’s binding specificity. Instead, AFAP1’s interactions seem tuned to kinases and membrane/linker proteins. In one study, AFAP1 was found to associate with p85 PI3K and facilitate localized PI3K activation in response to phorbol ester, further tying AFAP1 to the PI3K–Akt pathway (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Another study in breast cancer cells linked AFAP1 to NF-κB signaling: low molecular weight hyaluronan signals through CD44 and Toll-like receptors led to AFAP1–actin binding and an increase in MyD88-dependent NF-κB activation (www.nature.com). This suggests that AFAP1’s actin linkage can influence inflammatory signaling cascades in certain contexts. In summary, AFAP1 functions as a bridge between extracellular signals and the actin cytoskeleton, ensuring that enzymes like Src and PKC are activated at the right place and time to remodel the cytoskeleton. As an expert review summarized, AFAP1 acts as an adaptor that “brings signaling molecules to specialized signaling complexes and/or subcellular compartments, affecting the location and crosstalk between these molecules” (pmc.ncbi.nlm.nih.gov). Through this role, AFAP1 is involved in coordinating processes such as cell adhesion, migration, and invasion that require integration of signaling and cytoskeletal rearrangement (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

Cellular Localization and Function in Context

Consistent with its actin-related functions, AFAP1 is predominantly an intracellular, cytoskeletal protein. High-resolution imaging and fractionation studies place AFAP1 in the cytosol and along actin filaments, with enrichment at sites of actin assembly (v19.proteinatlas.org). The Human Protein Atlas indicates AFAP1 is localized to actin filament bundles and focal adhesions in cultured human cells (v19.proteinatlas.org) (v19.proteinatlas.org). It is not a secreted protein, nor is it typically found in the nucleus; rather, it concentrates wherever actin structures and signaling molecules converge. For example, in adherent cells AFAP1 can be seen at the termini of stress fibers where they insert into focal adhesions, consistent with its role in those structures (v19.proteinatlas.org). During active cell motility, a portion of AFAP1 also redistributes to the cell periphery, colocalizing with actin in lamellipodia or forming punctate spots at invadopodia/podosomes when those are induced (pubmed.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov). Studies in smooth muscle cells and macrophages have visualized AFAP1 at podosome rings and cores, where it likely helps anchor the podosome’s actin bundle and connect to signaling molecules like Src (www.nature.com) (www.nature.com). The subcellular targeting of AFAP1 is at least partly directed by its PH domains binding membrane phosphoinositides, which would recruit AFAP1 to the inner plasma membrane where actin polymerization is occurring (pmc.ncbi.nlm.nih.gov). Additionally, the ability of AFAP1 to bind PKC via the PH1 domain can localize PKC (and AFAP1 with it) to specific compartments, such as the cell cortex or periphery, upon PKC activation (pmc.ncbi.nlm.nih.gov). In the unique context of differentiated cells, AFAP1’s localization hints at specialized roles – for instance, in lactating mammary epithelial cells (discussed below), AFAP1 was found to concentrate at the apical surface of milk-secreting alveolar cells in complex with active Src (www.nature.com) (www.nature.com). This apical localization suggests AFAP1 can target Src to specific membrane domains (apical vs. basal) to regulate polarized cellular functions.

Functionally, AFAP1’s presence in these locations translates to roles in several biological processes:
- Cell Adhesion: By fortifying actin stress fibers and focal adhesions, AFAP1 promotes strong cell–matrix adhesion. Loss of AFAP1 leads to defective focal contacts and reduced adhesion strength (www.scholars.northwestern.edu) (www.scholars.northwestern.edu). AFAP1 thereby contributes to processes like cell spreading and mechanotransduction (sensing forces through focal adhesions).
- Cell Migration and Invasion: AFAP1 facilitates the dynamic rearrangement of the actin cytoskeleton needed for cell motility. It enables the formation of lamellipodia for migration and podosomes/invadopodia for invasive behavior (www.nature.com) (www.nature.com). In invasive cancer cells, AFAP1-driven actin changes can enhance cell migration through tissues.
- Signal Transduction: AFAP1’s scaffolding of Src and possibly other kinases means it helps propagate signals from integrins, growth factor receptors, and chemoattractant pathways to downstream effects like actin remodeling. It is involved in signaling cascades like Src–FAK (affecting cell movement and survival) and PKC–MAPK pathways (affecting proliferation and differentiation in some contexts) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).
- Secretory and Specialized Cellular Functions: Recent evidence suggests AFAP1 has roles in specialized cell functions that require actin remodeling. One notable example is in lactation: using an AFAP1 knockout mouse model, Ammer et al. (2014) showed that AFAP1 is required for proper milk secretion in the lactating mammary gland (www.nature.com) (www.nature.com). AFAP1-null female mice had impaired lactation characterized by accumulation of large intracellular lipid droplets and delayed secretion of milk lipids (www.nature.com). The underlying defect was tied to misregulation of c-Src – in normal lactation, prolactin hormone triggers AFAP1 to form a complex with c-Src (leading to AFAP1’s phosphorylation) and helps localize active Src to the apical side of mammary epithelial cells (www.nature.com). In the absence of AFAP1, active Src failed to localize apically and overall Src kinase activity in mammary tissue was reduced, resulting in improper signaling for milk lipid extrusion (www.nature.com) (www.nature.com). This was the first evidence of AFAP1 in a normal physiological process, and it “defined the requirement of AFAP1 for the spatial and temporal regulation of c-Src activity in the normal breast, specifically for milk production” (www.nature.com). Thus, AFAP1 can be crucial in contexts where actin-based secretion or cell shape changes are needed for function (another speculative example might be in immune cells: the Protein Atlas notes AFAP1 is elevated in eosinophils (v19.proteinatlas.org), which undergo actin-dependent degranulation and migration; it’s plausible AFAP1 contributes to those processes, though this remains to be studied).

In summary, at the cellular level AFAP1 acts at the interface of signaling and the cytoskeleton to influence a wide range of processes – from maintaining structural adhesion to enabling rapid actin reorganization for movement or secretion. By partitioning active kinases to specific sites, AFAP1 ensures that cells can swiftly reorganize their cytoskeleton in response to internal or external cues.

AFAP1 in Disease and Clinical Contexts

Given AFAP1’s central role in actin dynamics and Src signaling, it is perhaps not surprising that dysregulation of AFAP1 has been linked to cancer and other diseases. Many cancers exhibit aberrant activation of Src family kinases and cytoskeletal alterations that promote metastasis. AFAP1, as an upstream activator and scaffold of Src, often mirrors these oncogenic changes. Overexpression of AFAP1 has been observed in multiple tumor types, and it generally correlates with more aggressive disease. For example, in normal prostate epithelial cells, AFAP1 is either absent or expressed at very low levels, but in prostate carcinoma AFAP1 is significantly upregulated – with higher levels in tumors corresponding to higher Gleason grades (more advanced/aggressive cancers) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). A 2007 study by Zhang et al. found AFAP1 protein was barely detectable in benign prostate tissue but was elevated in a majority of prostate cancer specimens; the increase in AFAP1 expression tracked with tumor progression (pmc.ncbi.nlm.nih.gov). Functionally, this overexpression appears to enhance tumor cell survival and invasion: knocking down AFAP1 in prostate cancer cell lines (such as PC3) led to decreased cell proliferation, impaired cell-matrix adhesion, and reduced migration (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In mouse models of prostate cancer, AFAP1 depletion significantly inhibited tumor growth (pmc.ncbi.nlm.nih.gov). Notably, AFAP1-depleted prostate cancer cells showed defective focal adhesions and lower β1-integrin levels, consistent with the idea that AFAP1 is needed for maintaining focal contacts that allow tumor cells to adhere and signal for growth (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The same study demonstrated that re-introducing wild-type AFAP1 could rescue the aggressive traits of these cells, whereas a mutant AFAP1 unable to bind Src failed to do so (pmc.ncbi.nlm.nih.gov). Furthermore, an AFAP1 mutant lacking the PKC-interaction domain also did not restore the invasive properties, implying that both Src and PKC interactions are critical for AFAP1’s pro-tumor function in this context (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The authors concluded that AFAP1 contributes to prostate cancer progression by regulating focal contacts in a PKC-dependent manner (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

In invasive breast cancer cells (MDA-MB-231), as mentioned earlier, AFAP1 is required for stress fibers and adhesion, which might seem counterintuitive (as one might expect a metastatic cell to have fewer stress fibers). However, the ability to dynamically assemble or disassemble adhesions is key for invasion. AFAP1 provides the means to form focal adhesions (for traction) and, when signals demand, to break them down in favor of podosomes or invadopodia for matrix degradation (www.scholars.northwestern.edu) (www.scholars.northwestern.edu). Indeed, AFAP1 has been implicated in invadopodia formation and function in cancer cells. It co-localizes with actin and signaling proteins in these structures and affects their lifespan (www.nature.com). In vitro assays of invasive behavior often show that reducing AFAP1 levels impairs a cancer cell’s ability to degrade extracellular matrix, consistent with fewer or less stable invadopodia (www.nature.com). Moreover, AFAP1 interplay with integrin/Src signaling can influence epithelial–mesenchymal transition (EMT) and cell morphology in tumors (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Considering these roles, it’s not surprising that high AFAP1 expression has prognostic significance in some cancers. Data from large patient cohorts (e.g. via The Human Protein Atlas) indicate that AFAP1 mRNA levels serve as an unfavorable prognostic marker in lung cancer and renal cancer, where higher expression is associated with poorer survival (v19.proteinatlas.org) (v19.proteinatlas.org). This suggests AFAP1 could be used as part of a prognostic panel, although it’s not yet a routine clinical marker.

Another line of evidence linking AFAP1 to cancer is its coordination with Src. Src is frequently activated in cancers (but rarely mutated); instead, it’s hyper-activated by upstream signals. AFAP1 is one such upstream activator. In ovarian cancer, which often shows elevated Src activity, researchers found that AFAP1 is concomitantly upregulated. In an analysis of patient samples, over 90% of ovarian tumors showed increased AFAP1 expression alongside c-Src hyperactivity (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Furthermore, as mentioned, a significant fraction (~25%) of individuals carry a germline S403C variant in AFAP1 (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). While this variant alone is not a cancer-causing mutation, in the context of a tumor with high Src levels it can act as a “modifier”: Clump et al. (2010) reported that ovarian cancer cells with the AFAP1^403C variant activated Src and formed podosomes without the usual external PKC signal (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This means the variant AFAP1 can predispose cells to a pro-invasive, Src-active state more readily. The study proposed that this inherited variant could influence cancer progression in patients and might serve as a biomarker to predict who will respond to Src-inhibitor drugs (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In the era of precision medicine, such biomarkers are valuable; for instance, if a patient’s tumor both overexpresses Src and harbors AFAP1^403C, that tumor might be particularly dependent on the Src–AFAP1 axis and thus more sensitive to Src kinase inhibitors. This is an active area of investigation, although no specific anti-AFAP1 therapies exist yet.

Beyond cancer, AFAP1’s actin-regulatory function could be relevant to other pathologies. There is emerging interest in AFAP1’s gene locus in cardiovascular and fibrotic diseases, since actin and Src signaling modulate smooth muscle contraction and fibroblast activation. While direct studies are limited, it’s noteworthy that some omics screens have picked up dysregulation of AFAP1 or its antisense transcript in conditions like atherosclerosis and tissue fibrosis (synapse.patsnap.com). However, the clearest non-cancer role identified so far remains the lactation defect in AFAP1-knockout mice, illustrating that AFAP1 may be critical in any process requiring coordinated Src signaling and actin rearrangement (e.g. regulated secretion, immune cell activation, wound healing).

Recent Developments (2023–2024) and Future Directions

Research on AFAP1 continues to evolve, with recent studies (2021–2024) expanding our understanding of how this protein is regulated and how it impacts disease. One notable development is the recognition of AFAP1-AS1, a long non-coding RNA transcribed from the AFAP1 gene locus, which does not code for the AFAP1 protein but can influence its expression. AFAP1-AS1 has gained attention as an oncogenic lncRNA in a variety of cancers and serves as an example of how AFAP1 is embedded in a larger regulatory network. AFAP1-AS1 is frequently overexpressed in tumors (including lung, breast, gastric, and others), and high AFAP1-AS1 levels correlate with enhanced migration, invasion, and poor prognosis (pubmed.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov). Mechanistic studies in 2021 demonstrated that AFAP1-AS1 can act as a competing endogenous RNA (ceRNA) – specifically, it sponges microRNAs such as miR-205-5p that would otherwise suppress AFAP1 expression (pubmed.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov). In gastric cancer cells, silencing AFAP1-AS1 led to lowered AFAP1 protein levels and a marked decrease in cell proliferation and invasiveness, effects that could be reversed by modulating miR-205 and AFAP1 (pubmed.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov). This suggests that a significant part of AFAP1-AS1’s pro-tumor activity is due to upregulation of the AFAP1 protein. Consequently, AFAP1-AS1 and its controlled network (AFAP1-AS1/miR-205/AFAP1) have been proposed as therapeutic targets or biomarkers. In 2024, a comprehensive review in Current Pharmaceutical Design highlighted AFAP1-AS1’s role across gynecologic and urogenital cancers (synapse.patsnap.com), underscoring that therapies aiming to inhibit this lncRNA might indirectly curb AFAP1-driven pathways in cancer cells.

Another recent research avenue involves extracellular vesicles and circular RNAs affecting AFAP1. A 2024 study reported that an exosomal circular RNA derived from human mesenchymal stem cells can suppress cholangiocarcinoma progression by modulating a microRNA that targets AFAP1 (synapse.patsnap.com). In that study, the exosomal circRNA acted as a sponge for miR-620, relieving miR-620’s inhibition of AFAP1, thereby altering the behavior of cholangiocarcinoma cells (synapse.patsnap.com). Interestingly, in this particular context, increasing AFAP1 was associated with inhibition of tumor progression, which hints at cell-type specific roles or a complex interplay (it's possible that in cholangiocarcinoma stroma or specific subtypes, AFAP1 might exert different effects, or that the circRNA has additional targets). Nonetheless, it illustrates the current interest in the AFAP1 axis in cancer: researchers are looking not just at the protein itself, but at upstream regulators (lncRNAs, circRNAs, miRNAs) that fine-tune AFAP1 expression in disease states. These findings open the door to novel therapeutic strategies – for instance, delivering a competing oligonucleotide to soak up AFAP1-AS1, or using exosome-mediated transfer of circRNAs or miRNA mimics/inhibitors to modulate AFAP1 levels in tumors.

On the clinical research front, efforts are being made to translate knowledge of AFAP1 into clinical markers. Large-scale genomic studies in 2023 have started to identify rare variants in AFAP1 that might contribute to disease beyond cancer. For example, a 2024 precision oncology study investigating unexplained cases of familial adenomatous polyposis (FAP) – a hereditary colon cancer syndrome – utilized DNA/RNA sequencing to uncover non-APC gene contributors (synapse.patsnap.com). Intriguingly, that study (JCO Precision Oncology, May 2024) identified anomalies in AFAP1 transcripts in certain patients, suggesting that cryptic alterations in AFAP1 could underlie some cancer-predisposition in the colon (this is still a developing area, and the term “AFAP” in gastroenterology also refers to an attenuated form of polyposis, so follow-up work is needed to confirm AFAP1’s role). Nonetheless, the inclusion of AFAP1 in such cutting-edge diagnostics underscores its growing recognition.

From a therapeutic perspective, AFAP1 is not an enzyme and thus not a classic drug target, but its position at a convergence of PKC and Src pathways makes it attractive to consider in combination therapies. Src kinase inhibitors (like dasatinib) have had mixed success in solid tumors; one hypothesis is that patient stratification based on AFAP1 activity or expression could improve their efficacy. For instance, tumors with high AFAP1 (or the AFAP1^403C variant) might rely heavily on the Src-AFAP1 axis and thus be more vulnerable to Src inhibition (pmc.ncbi.nlm.nih.gov). Conversely, if AFAP1 is low, Src might be less critical or activated through alternate routes. As research moves forward, AFAP1 levels or genotype could become part of a biomarker panel to guide the use of Src inhibitors or perhaps PKC modulators. Additionally, disrupting the AFAP1–Src interaction is a conceivable strategy; some researchers have suggested designing peptides or small molecules that mask AFAP1’s SH3-binding motif or phospho-tyrosine motifs, thereby preventing it from activating Src. While still in preclinical stages, such interventions could potentially block invasive behavior in metastatic cancers with fewer side effects than broad kinase inhibitors.

In conclusion, AFAP1 (Actin Filament-Associated Protein 1) is a versatile actin-binding adaptor that plays a crucial role in connecting signal transduction to cytoskeletal remodeling. Key concepts include its domain-mediated regulation (PH domains, leucine zipper, etc.), its ability to cross-link actin filaments, and its function in activating and localizing Src family kinases. Current understanding solidifies AFAP1 as both a stabilizer of actin structures and a facilitator of dynamic actin reorganization in response to signals. Recent research (2021–2024) has shed light on the gene’s regulation by non-coding RNAs and hinted at clinical relevance in prognostics and personalized therapy. Real-world implementations are on the horizon: for example, AFAP1 is already noted as an unfavorable prognostic marker in certain cancers (v19.proteinatlas.org), and its genetic variants may inform treatment choices (pmc.ncbi.nlm.nih.gov). Expert analyses from leading studies describe AFAP1 as an essential mediator that “affects crosstalk between Src and PKC” and coordinates the assembly/disassembly of actin networks (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). As such, AFAP1 is an important node in cell biology, and continuing to unravel its interactions and regulation holds promise for understanding diseases driven by cytoskeletal dysfunction and dysregulated signaling.

References: Publications cited above include foundational studies such as Flynn et al. 1993 (AFAP1 discovery), Baisden et al. 2001 (www.nature.com), which first articulated AFAP1’s adaptor role and structure; Qian et al. 2002 (pmc.ncbi.nlm.nih.gov) on PKC phosphorylation effects; Gatesman et al. 2004 (pmc.ncbi.nlm.nih.gov) on PKC–Src–podosome signaling; Dorfleutner et al. 2007 (www.scholars.northwestern.edu) on AFAP1 in adhesion; Zhang et al. 2007 (J Clin Invest) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov) on AFAP1 in prostate cancer; Clump et al. 2010 (pmc.ncbi.nlm.nih.gov) on the AFAP1^403C variant; and Ammer et al. 2014 (www.nature.com) (www.nature.com) demonstrating AFAP1’s physiological role in mammary gland function, among others. These and more recent sources (Dang et al. 2021 (pubmed.ncbi.nlm.nih.gov), Wen et al. 2024, etc.) collectively provide a comprehensive view of AFAP1 as a critical link between cellular signals and the actin cytoskeleton, with significant implications for health and disease.

Citations

1. AnnotationURLCitation(end_index=293, start_index=170, title='AFAP1 actin filament associated protein 1 [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene/60312#:~:text=Summary%20The%20protein%20encoded%20by,Expression')
2. AnnotationURLCitation(end_index=746, start_index=615, title='The actin filament-associated protein AFAP-110 is an adaptor protein that modulates changes in actin filament integrity | Oncogene', type='url_citation', url='https://www.nature.com/articles/1204784#:~:text=The%20actin%20filament,an%20intrinsic%20capability%20to%20alter')
3. AnnotationURLCitation(end_index=1053, start_index=906, title='The actin filament-associated protein AFAP-110 is an adaptor protein that modulates changes in actin filament integrity | Oncogene', type='url_citation', url='https://www.nature.com/articles/1204784#:~:text=actin%20filament%20integrity%20that%20can,will%20review%20the%20structure%20and')
4. AnnotationURLCitation(end_index=1411, start_index=1229, title='AFAP1 protein expression summary - The Human Protein Atlas', type='url_citation', url='https://v19.proteinatlas.org/ENSG00000196526-AFAP1#:~:text=Gene%20name%5E%7Bi%7D%20AFAP1%20%28AFAP%2C%20AFAP,i%7D%20Immune%20cell%20enhanced%20%28eosinophil')
5. AnnotationURLCitation(end_index=1737, start_index=1555, title='AFAP1 protein expression summary - The Human Protein Atlas', type='url_citation', url='https://v19.proteinatlas.org/ENSG00000196526-AFAP1#:~:text=Gene%20name%5E%7Bi%7D%20AFAP1%20%28AFAP%2C%20AFAP,i%7D%20Immune%20cell%20enhanced%20%28eosinophil')
6. AnnotationURLCitation(end_index=2208, start_index=2030, title='AFAP1 protein expression summary - The Human Protein Atlas', type='url_citation', url='https://v19.proteinatlas.org/ENSG00000196526-AFAP1#:~:text=Cancer%20prognostic%20summary%20Prognostic%20marker,actin%20filaments%20into%20both%20network')
7. AnnotationURLCitation(end_index=2355, start_index=2209, title='AFAP1 protein expression summary - The Human Protein Atlas', type='url_citation', url='https://v19.proteinatlas.org/ENSG00000196526-AFAP1#:~:text=%28unfavourable%29%20Brain%20specificity,i%7D%20Intracellular')
8. AnnotationURLCitation(end_index=3042, start_index=2882, title='The actin filament-associated protein AFAP-110 is an adaptor protein that modulates changes in actin filament integrity | Oncogene', type='url_citation', url='https://www.nature.com/articles/1204784#:~:text=two%20pleckstrin%20homology%20domains%2C%20a,family%20members%20and%2For%20other%20signaling')
9. AnnotationURLCitation(end_index=3166, start_index=3043, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=AFAP,motifs%20are%20involved%20in%20the')
10. AnnotationURLCitation(end_index=3603, start_index=3424, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=functional%20domains%2C%20including%202%20pleckstrin,domains%20may%20potentially%20direct%20the')
11. AnnotationURLCitation(end_index=3849, start_index=3724, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=contains%20a%20carboxyterminal%20actin,16')
12. AnnotationURLCitation(end_index=3979, start_index=3850, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=AFAP,proteins%2C%20such%20as%20the%20receptor')
13. AnnotationURLCitation(end_index=4306, start_index=4181, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=contains%20a%20carboxyterminal%20actin,16')
14. AnnotationURLCitation(end_index=4437, start_index=4307, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=domain%2C%20which%20allows%20the%20formation,5')
15. AnnotationURLCitation(end_index=4777, start_index=4652, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=contains%20a%20carboxyterminal%20actin,16')
16. AnnotationURLCitation(end_index=4908, start_index=4778, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=domain%2C%20which%20allows%20the%20formation,5')
17. AnnotationURLCitation(end_index=5311, start_index=5158, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=www.ncbi.nlm.nih.gov%20%29.%20AFAP,activated%20cSrc%20to%20the%20cell')
18. AnnotationURLCitation(end_index=5775, start_index=5617, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=in%20exon%209%20that%20predicts,110%5E%7B%CE%94Lzip%7D%29%20or%20on%20PKCa')
19. AnnotationURLCitation(end_index=5974, start_index=5776, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=intermolecular%20interaction%20between%20the%20carboxy,rich%20invasive%20structures%E2%80%94podosomes%20%5B14%2C16')
20. AnnotationURLCitation(end_index=6476, start_index=6316, title='The actin filament-associated protein AFAP-110 is an adaptor protein that modulates changes in actin filament integrity | Oncogene', type='url_citation', url='https://www.nature.com/articles/1204784#:~:text=two%20pleckstrin%20homology%20domains%2C%20a,family%20members%20and%2For%20other%20signaling')
21. AnnotationURLCitation(end_index=6606, start_index=6477, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=AFAP,proteins%2C%20such%20as%20the%20receptor')
22. AnnotationURLCitation(end_index=6973, start_index=6848, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=contains%20a%20carboxyterminal%20actin,16')
23. AnnotationURLCitation(end_index=7103, start_index=6974, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=AFAP,proteins%2C%20such%20as%20the%20receptor')
24. AnnotationURLCitation(end_index=7381, start_index=7221, title='The actin filament-associated protein AFAP-110 is an adaptor protein that modulates changes in actin filament integrity | Oncogene', type='url_citation', url='https://www.nature.com/articles/1204784#:~:text=two%20pleckstrin%20homology%20domains%2C%20a,family%20members%20and%2For%20other%20signaling')
25. AnnotationURLCitation(end_index=7949, start_index=7824, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=contains%20a%20carboxyterminal%20actin,16')
26. AnnotationURLCitation(end_index=8080, start_index=7950, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=domain%2C%20which%20allows%20the%20formation,5')
27. AnnotationURLCitation(end_index=8662, start_index=8502, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=Scholar%20scholar.google.com%20%5D%20,directed%20activation%20of%20cSrc%20by')
28. AnnotationURLCitation(end_index=8799, start_index=8663, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=T%2C%20Pustula%20J%2C%20Zot%20HG%2C,Google%20Scholar')
29. AnnotationURLCitation(end_index=9117, start_index=8957, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=Scholar%20scholar.google.com%20%5D%20,directed%20activation%20of%20cSrc%20by')
30. AnnotationURLCitation(end_index=9297, start_index=9118, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=functional%20domains%2C%20including%202%20pleckstrin,domains%20may%20potentially%20direct%20the')
31. AnnotationURLCitation(end_index=9666, start_index=9513, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=www.ncbi.nlm.nih.gov%20%29.%20AFAP,activated%20cSrc%20to%20the%20cell')
32. AnnotationURLCitation(end_index=9846, start_index=9667, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=functional%20domains%2C%20including%202%20pleckstrin,domains%20may%20potentially%20direct%20the')
33. AnnotationURLCitation(end_index=10220, start_index=10060, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=Scholar%20scholar.google.com%20%5D%20,directed%20activation%20of%20cSrc%20by')
34. AnnotationURLCitation(end_index=10357, start_index=10221, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=T%2C%20Pustula%20J%2C%20Zot%20HG%2C,Google%20Scholar')
35. AnnotationURLCitation(end_index=10975, start_index=10798, title='AFAP-110 is required for actin stress fiber formation and cell adhesion in MDA-MB-231 breast cancer cells - Northwestern Scholars', type='url_citation', url='https://www.scholars.northwestern.edu/en/publications/afap-110-is-required-for-actin-stress-fiber-formation-and-cell-ad/#:~:text=AFAP,Although')
36. AnnotationURLCitation(end_index=11223, start_index=10976, title='AFAP-110 is required for actin stress fiber formation and cell adhesion in MDA-MB-231 breast cancer cells - Northwestern Scholars', type='url_citation', url='https://www.scholars.northwestern.edu/en/publications/afap-110-is-required-for-actin-stress-fiber-formation-and-cell-ad/#:~:text=changes%20in%20cell%20proliferation%20but,components%20were%20not%20influenced%20by')
37. AnnotationURLCitation(end_index=11615, start_index=11438, title='AFAP-110 is required for actin stress fiber formation and cell adhesion in MDA-MB-231 breast cancer cells - Northwestern Scholars', type='url_citation', url='https://www.scholars.northwestern.edu/en/publications/afap-110-is-required-for-actin-stress-fiber-formation-and-cell-ad/#:~:text=AFAP,Although')
38. AnnotationURLCitation(end_index=11876, start_index=11616, title='AFAP-110 is required for actin stress fiber formation and cell adhesion in MDA-MB-231 breast cancer cells - Northwestern Scholars', type='url_citation', url='https://www.scholars.northwestern.edu/en/publications/afap-110-is-required-for-actin-stress-fiber-formation-and-cell-ad/#:~:text=cytoskeletal%20tension%20through%20stress%20fiber,would%20promote%20focal%20adhesion%20formation')
39. AnnotationURLCitation(end_index=12264, start_index=12028, title='AFAP-110 is required for actin stress fiber formation and cell adhesion in MDA-MB-231 breast cancer cells - Northwestern Scholars', type='url_citation', url='https://www.scholars.northwestern.edu/en/publications/afap-110-is-required-for-actin-stress-fiber-formation-and-cell-ad/#:~:text=approach%20confirms%20that%20MDA,231%20breast%20cancer%20cell%20adhesion')
40. AnnotationURLCitation(end_index=12525, start_index=12265, title='AFAP-110 is required for actin stress fiber formation and cell adhesion in MDA-MB-231 breast cancer cells - Northwestern Scholars', type='url_citation', url='https://www.scholars.northwestern.edu/en/publications/afap-110-is-required-for-actin-stress-fiber-formation-and-cell-ad/#:~:text=cytoskeletal%20tension%20through%20stress%20fiber,would%20promote%20focal%20adhesion%20formation')
41. AnnotationURLCitation(end_index=12933, start_index=12697, title='AFAP-110 is required for actin stress fiber formation and cell adhesion in MDA-MB-231 breast cancer cells - Northwestern Scholars', type='url_citation', url='https://www.scholars.northwestern.edu/en/publications/afap-110-is-required-for-actin-stress-fiber-formation-and-cell-ad/#:~:text=approach%20confirms%20that%20MDA,231%20breast%20cancer%20cell%20adhesion')
42. AnnotationURLCitation(end_index=13194, start_index=12934, title='AFAP-110 is required for actin stress fiber formation and cell adhesion in MDA-MB-231 breast cancer cells - Northwestern Scholars', type='url_citation', url='https://www.scholars.northwestern.edu/en/publications/afap-110-is-required-for-actin-stress-fiber-formation-and-cell-ad/#:~:text=cytoskeletal%20tension%20through%20stress%20fiber,would%20promote%20focal%20adhesion%20formation')
43. AnnotationURLCitation(end_index=13596, start_index=13360, title='AFAP-110 is required for actin stress fiber formation and cell adhesion in MDA-MB-231 breast cancer cells - Northwestern Scholars', type='url_citation', url='https://www.scholars.northwestern.edu/en/publications/afap-110-is-required-for-actin-stress-fiber-formation-and-cell-ad/#:~:text=approach%20confirms%20that%20MDA,231%20breast%20cancer%20cell%20adhesion')
44. AnnotationURLCitation(end_index=13857, start_index=13597, title='AFAP-110 is required for actin stress fiber formation and cell adhesion in MDA-MB-231 breast cancer cells - Northwestern Scholars', type='url_citation', url='https://www.scholars.northwestern.edu/en/publications/afap-110-is-required-for-actin-stress-fiber-formation-and-cell-ad/#:~:text=cytoskeletal%20tension%20through%20stress%20fiber,would%20promote%20focal%20adhesion%20formation')
45. AnnotationURLCitation(end_index=14339, start_index=14079, title='AFAP-110 is required for actin stress fiber formation and cell adhesion in MDA-MB-231 breast cancer cells - Northwestern Scholars', type='url_citation', url='https://www.scholars.northwestern.edu/en/publications/afap-110-is-required-for-actin-stress-fiber-formation-and-cell-ad/#:~:text=cytoskeletal%20tension%20through%20stress%20fiber,would%20promote%20focal%20adhesion%20formation')
46. AnnotationURLCitation(end_index=14572, start_index=14340, title='AFAP-110 is required for actin stress fiber formation and cell adhesion in MDA-MB-231 breast cancer cells - Northwestern Scholars', type='url_citation', url='https://www.scholars.northwestern.edu/en/publications/afap-110-is-required-for-actin-stress-fiber-formation-and-cell-ad/#:~:text=adhesions%20in%20AFAP,would%20promote%20focal%20adhesion%20formation')
47. AnnotationURLCitation(end_index=15082, start_index=14932, title='Actin filament-associated protein 1 is required for cSrc activity and secretory activation in the lactating mammary gland | Oncogene', type='url_citation', url='https://www.nature.com/articles/onc2014205#:~:text=binds%20to%20filamentous%20actin%20and,the%20lactating%20knockout%20mice%20were')
48. AnnotationURLCitation(end_index=15231, start_index=15083, title='Actin filament-associated protein 1 is required for cSrc activity and secretory activation in the lactating mammary gland | Oncogene', type='url_citation', url='https://www.nature.com/articles/onc2014205#:~:text=prostate%20cancer%20cells%2C%20AFAP1%20has,in%20lipid%20synthesis%20and%20the')
49. AnnotationURLCitation(end_index=15663, start_index=15535, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=,0148.%20%5BDOI%5D%20%5BPMC%20free%20article')
50. AnnotationURLCitation(end_index=15789, start_index=15664, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=Scholar%20scholar.google.com%20%5D%20,doi')
51. AnnotationURLCitation(end_index=16138, start_index=15951, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=%5B12%2C13%20%5D.%20In%20addition%2C%20AFAP,rich%20invasive%20structures%E2%80%94podosomes%20%5B14%2C16')
52. AnnotationURLCitation(end_index=16337, start_index=16139, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=intermolecular%20interaction%20between%20the%20carboxy,rich%20invasive%20structures%E2%80%94podosomes%20%5B14%2C16')
53. AnnotationURLCitation(end_index=16614, start_index=16486, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=,0148.%20%5BDOI%5D%20%5BPMC%20free%20article')
54. AnnotationURLCitation(end_index=16751, start_index=16615, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=T%2C%20Pustula%20J%2C%20Zot%20HG%2C,Google%20Scholar')
55. AnnotationURLCitation(end_index=17281, start_index=17123, title='Actin filament-associated protein 1 is required for cSrc activity and secretory activation in the lactating mammary gland | Oncogene', type='url_citation', url='https://www.nature.com/articles/onc2014205#:~:text=ability%20to%20alter%20actin%20filament,Cell%20Res%202000%3B%20255%3A%20102%E2%80%93113')
56. AnnotationURLCitation(end_index=17761, start_index=17669, title='Actin filament-associated protein 1 is required for cSrc activity and secretory activation in the lactating mammary gland | Oncogene', type='url_citation', url='https://www.nature.com/articles/onc2014205#:~:text=motif,110%E2%80%93119')
57. AnnotationURLCitation(end_index=18171, start_index=18032, title='The actin filament-associated protein AFAP-110 is an adaptor protein that modulates changes in actin filament integrity | Oncogene', type='url_citation', url='https://www.nature.com/articles/1204784#:~:text=as%20an%20adaptor%20protein%20by,to%20cellular%20signals%20that%20alter')
58. AnnotationURLCitation(end_index=18319, start_index=18172, title='The actin filament-associated protein AFAP-110 is an adaptor protein that modulates changes in actin filament integrity | Oncogene', type='url_citation', url='https://www.nature.com/articles/1204784#:~:text=actin%20filament%20integrity%20that%20can,will%20review%20the%20structure%20and')
59. AnnotationURLCitation(end_index=18646, start_index=18523, title='AFAP1 actin filament associated protein 1 [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene/60312#:~:text=Summary%20The%20protein%20encoded%20by,Expression')
60. AnnotationURLCitation(end_index=18786, start_index=18647, title='The actin filament-associated protein AFAP-110 is an adaptor protein that modulates changes in actin filament integrity | Oncogene', type='url_citation', url='https://www.nature.com/articles/1204784#:~:text=as%20an%20adaptor%20protein%20by,to%20cellular%20signals%20that%20alter')
61. AnnotationURLCitation(end_index=19035, start_index=18887, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=The%20actin%20filament%E2%80%93associated%20protein%20of,binding')
62. AnnotationURLCitation(end_index=19404, start_index=19240, title='AFAP1L1 is a novel adaptor protein of the AFAP family that interacts with cortactin and localizes to invadosomes - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/21333378/#:~:text=AFAP1L1%20is%20hypothesized%20to%20have,move%20to%20podosomes%20without%20stimulation')
63. AnnotationURLCitation(end_index=19563, start_index=19405, title='AFAP1L1 is a novel adaptor protein of the AFAP family that interacts with cortactin and localizes to invadosomes - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/21333378/#:~:text=tyrosine%20kinase%20cSrc%20via%20an,in%20human%20tissues%20shows%20differential')
64. AnnotationURLCitation(end_index=20024, start_index=19900, title='Actin filament-associated protein 1 is required for cSrc activity and secretory activation in the lactating mammary gland | Oncogene', type='url_citation', url='https://www.nature.com/articles/onc2014205#:~:text=4,Cell%20Biochem%201997%3B%20175%3A%20243%E2%80%93252')
65. AnnotationURLCitation(end_index=20150, start_index=20025, title='Actin filament-associated protein 1 is required for cSrc activity and secretory activation in the lactating mammary gland | Oncogene', type='url_citation', url='https://www.nature.com/articles/onc2014205#:~:text=5,Mol%20Carcinogen%201998%3B%2022%3A%20110%E2%80%93119')
66. AnnotationURLCitation(end_index=20400, start_index=20271, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=AFAP,proteins%2C%20such%20as%20the%20receptor')
67. AnnotationURLCitation(end_index=20532, start_index=20401, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=AFAP,domains%20may%20potentially%20direct%20the')
68. AnnotationURLCitation(end_index=20746, start_index=20622, title='Actin filament-associated protein 1 is required for cSrc activity and secretory activation in the lactating mammary gland | Oncogene', type='url_citation', url='https://www.nature.com/articles/onc2014205#:~:text=4,Cell%20Biochem%201997%3B%20175%3A%20243%E2%80%93252')
69. AnnotationURLCitation(end_index=21354, start_index=21181, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=Enhanced%20expression%20and%20activity%20of,presence%20of%20a%20nonsynonymous%2C%20single')
70. AnnotationURLCitation(end_index=21517, start_index=21355, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=that%20releases%20its%20autoinhibition,of%20input%20signals%2C%20in%20contrast')
71. AnnotationURLCitation(end_index=21806, start_index=21644, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=that%20releases%20its%20autoinhibition,of%20input%20signals%2C%20in%20contrast')
72. AnnotationURLCitation(end_index=22174, start_index=22012, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=that%20releases%20its%20autoinhibition,of%20input%20signals%2C%20in%20contrast')
73. AnnotationURLCitation(end_index=22583, start_index=22430, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=www.ncbi.nlm.nih.gov%20%29.%20AFAP,activated%20cSrc%20to%20the%20cell')
74. AnnotationURLCitation(end_index=22782, start_index=22584, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=intermolecular%20interaction%20between%20the%20carboxy,rich%20invasive%20structures%E2%80%94podosomes%20%5B14%2C16')
75. AnnotationURLCitation(end_index=23087, start_index=22925, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=that%20releases%20its%20autoinhibition,of%20input%20signals%2C%20in%20contrast')
76. AnnotationURLCitation(end_index=23252, start_index=23088, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=activates%20cSrc%20through%20a%20direct,that%2C%20under%20conditions%20of%20cSrc')
77. AnnotationURLCitation(end_index=23523, start_index=23399, title='Actin filament-associated protein 1 is required for cSrc activity and secretory activation in the lactating mammary gland | Oncogene', type='url_citation', url='https://www.nature.com/articles/onc2014205#:~:text=4,Cell%20Biochem%201997%3B%20175%3A%20243%E2%80%93252')
78. AnnotationURLCitation(end_index=23649, start_index=23524, title='Actin filament-associated protein 1 is required for cSrc activity and secretory activation in the lactating mammary gland | Oncogene', type='url_citation', url='https://www.nature.com/articles/onc2014205#:~:text=5,Mol%20Carcinogen%201998%3B%2022%3A%20110%E2%80%93119')
79. AnnotationURLCitation(end_index=24066, start_index=23904, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=that%20releases%20its%20autoinhibition,of%20input%20signals%2C%20in%20contrast')
80. AnnotationURLCitation(end_index=24202, start_index=24067, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=increase%20of%20AFAP,be%20used%20to%20predict%20the')
81. AnnotationURLCitation(end_index=24522, start_index=24387, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=increase%20of%20AFAP,be%20used%20to%20predict%20the')
82. AnnotationURLCitation(end_index=24681, start_index=24523, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=that%20express%20enhanced%20levels%20of,110%20promotes%20cSrc%20activation')
83. AnnotationURLCitation(end_index=24995, start_index=24867, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=,0148.%20%5BDOI%5D%20%5BPMC%20free%20article')
84. AnnotationURLCitation(end_index=25156, start_index=24996, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=Scholar%20scholar.google.com%20%5D%20,directed%20activation%20of%20cSrc%20by')
85. AnnotationURLCitation(end_index=25398, start_index=25219, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=functional%20domains%2C%20including%202%20pleckstrin,domains%20may%20potentially%20direct%20the')
86. AnnotationURLCitation(end_index=25699, start_index=25571, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=,0148.%20%5BDOI%5D%20%5BPMC%20free%20article')
87. AnnotationURLCitation(end_index=25836, start_index=25700, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=T%2C%20Pustula%20J%2C%20Zot%20HG%2C,Google%20Scholar')
88. AnnotationURLCitation(end_index=26179, start_index=26058, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=doi%3A%2010.1091%2Fmbc.E01,Monoclonal')
89. AnnotationURLCitation(end_index=26495, start_index=26338, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=association%20of%20AFAP,in%20regulating%20multiple%20cellular%20processes')
90. AnnotationURLCitation(end_index=26814, start_index=26657, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=association%20of%20AFAP,in%20regulating%20multiple%20cellular%20processes')
91. AnnotationURLCitation(end_index=27142, start_index=27013, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=%288%20%29.%20Both%20amino,based%20structures')
92. AnnotationURLCitation(end_index=27288, start_index=27143, title='Actin filament-associated protein 1 is required for cSrc activity and secretory activation in the lactating mammary gland | Oncogene', type='url_citation', url='https://www.nature.com/articles/onc2014205#:~:text=study%20also%20demonstrated%20that%20AFAP1,in%20the%20absence%20of%20AFAP1')
93. AnnotationURLCitation(end_index=28031, start_index=27841, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=Disruption%20of%20actin%20organization%20abrogates,evidence%20demonstrates%20the%20multifunctional%20roles')
94. AnnotationURLCitation(end_index=28194, start_index=28032, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=structures%20and%20disturbs%20integrin,bundling%20protein%2C%20is%20frequently')
95. AnnotationURLCitation(end_index=28557, start_index=28443, title='The actin filament-associated protein AFAP-110 is an adaptor protein that modulates changes in actin filament integrity | Oncogene', type='url_citation', url='https://www.nature.com/articles/1204784#:~:text=AFAP,to%20alter%20actin%20filament%20integrity')
96. AnnotationURLCitation(end_index=29053, start_index=28889, title='AFAP1L1 is a novel adaptor protein of the AFAP family that interacts with cortactin and localizes to invadosomes - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/21333378/#:~:text=AFAP1L1%20is%20hypothesized%20to%20have,move%20to%20podosomes%20without%20stimulation')
97. AnnotationURLCitation(end_index=29212, start_index=29054, title='AFAP1L1 is a novel adaptor protein of the AFAP family that interacts with cortactin and localizes to invadosomes - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/21333378/#:~:text=tyrosine%20kinase%20cSrc%20via%20an,in%20human%20tissues%20shows%20differential')
98. AnnotationURLCitation(end_index=29650, start_index=29529, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=doi%3A%2010.1091%2Fmbc.E01,Monoclonal')
99. AnnotationURLCitation(end_index=29752, start_index=29651, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=,Google%20Scholar')
100. AnnotationURLCitation(end_index=30130, start_index=29984, title='Actin filament-associated protein 1 is required for cSrc activity and secretory activation in the lactating mammary gland | Oncogene', type='url_citation', url='https://www.nature.com/articles/onc2014205#:~:text=regulating%20focal%20contacts,Invest%202007%3B%20117%3A%202962%E2%80%932973')
101. AnnotationURLCitation(end_index=30805, start_index=30676, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=%288%20%29.%20Both%20amino,based%20structures')
102. AnnotationURLCitation(end_index=31176, start_index=30986, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=Disruption%20of%20actin%20organization%20abrogates,evidence%20demonstrates%20the%20multifunctional%20roles')
103. AnnotationURLCitation(end_index=31339, start_index=31177, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=structures%20and%20disturbs%20integrin,bundling%20protein%2C%20is%20frequently')
104. AnnotationURLCitation(end_index=31838, start_index=31656, title='AFAP1 protein expression summary - The Human Protein Atlas', type='url_citation', url='https://v19.proteinatlas.org/ENSG00000196526-AFAP1#:~:text=Gene%20name%5E%7Bi%7D%20AFAP1%20%28AFAP%2C%20AFAP,i%7D%20Immune%20cell%20enhanced%20%28eosinophil')
105. AnnotationURLCitation(end_index=32149, start_index=31967, title='AFAP1 protein expression summary - The Human Protein Atlas', type='url_citation', url='https://v19.proteinatlas.org/ENSG00000196526-AFAP1#:~:text=Gene%20name%5E%7Bi%7D%20AFAP1%20%28AFAP%2C%20AFAP,i%7D%20Immune%20cell%20enhanced%20%28eosinophil')
106. AnnotationURLCitation(end_index=32299, start_index=32150, title='AFAP1 protein expression summary - The Human Protein Atlas', type='url_citation', url='https://v19.proteinatlas.org/ENSG00000196526-AFAP1#:~:text=Subcellular%20location,actin%20filaments%20into%20both%20network')
107. AnnotationURLCitation(end_index=32772, start_index=32623, title='AFAP1 protein expression summary - The Human Protein Atlas', type='url_citation', url='https://v19.proteinatlas.org/ENSG00000196526-AFAP1#:~:text=Subcellular%20location,actin%20filaments%20into%20both%20network')
108. AnnotationURLCitation(end_index=33138, start_index=32986, title='AFAP1L1 is a novel adaptor protein of the AFAP family that interacts with cortactin and localizes to invadosomes - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/21333378/#:~:text=interacting%20with%20the%20SH3%20domain,brain%20where%20AFAP1%20was%20not')
109. AnnotationURLCitation(end_index=33314, start_index=33139, title='AFAP1L1 is a novel adaptor protein of the AFAP family that interacts with cortactin and localizes to invadosomes - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/21333378/#:~:text=structures%20and%20colocalize%20with%20cortactin%2C,unique%20protein%20interactions%20in%20which')
110. AnnotationURLCitation(end_index=33665, start_index=33515, title='Actin filament-associated protein 1 is required for cSrc activity and secretory activation in the lactating mammary gland | Oncogene', type='url_citation', url='https://www.nature.com/articles/onc2014205#:~:text=binds%20to%20filamentous%20actin%20and,the%20lactating%20knockout%20mice%20were')
111. AnnotationURLCitation(end_index=33814, start_index=33666, title='Actin filament-associated protein 1 is required for cSrc activity and secretory activation in the lactating mammary gland | Oncogene', type='url_citation', url='https://www.nature.com/articles/onc2014205#:~:text=prostate%20cancer%20cells%2C%20AFAP1%20has,in%20lipid%20synthesis%20and%20the')
112. AnnotationURLCitation(end_index=34189, start_index=34032, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=association%20of%20AFAP,in%20regulating%20multiple%20cellular%20processes')
113. AnnotationURLCitation(end_index=34557, start_index=34378, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=functional%20domains%2C%20including%202%20pleckstrin,domains%20may%20potentially%20direct%20the')
114. AnnotationURLCitation(end_index=34989, start_index=34844, title='Actin filament-associated protein 1 is required for cSrc activity and secretory activation in the lactating mammary gland | Oncogene', type='url_citation', url='https://www.nature.com/articles/onc2014205#:~:text=study%20also%20demonstrated%20that%20AFAP1,in%20the%20absence%20of%20AFAP1')
115. AnnotationURLCitation(end_index=35132, start_index=34990, title='Actin filament-associated protein 1 is required for cSrc activity and secretory activation in the lactating mammary gland | Oncogene', type='url_citation', url='https://www.nature.com/articles/onc2014205#:~:text=activation%20in%20the%20cSrc%20knockout,in%20the%20absence%20of%20AFAP1')
116. AnnotationURLCitation(end_index=35825, start_index=35589, title='AFAP-110 is required for actin stress fiber formation and cell adhesion in MDA-MB-231 breast cancer cells - Northwestern Scholars', type='url_citation', url='https://www.scholars.northwestern.edu/en/publications/afap-110-is-required-for-actin-stress-fiber-formation-and-cell-ad/#:~:text=approach%20confirms%20that%20MDA,231%20breast%20cancer%20cell%20adhesion')
117. AnnotationURLCitation(end_index=36086, start_index=35826, title='AFAP-110 is required for actin stress fiber formation and cell adhesion in MDA-MB-231 breast cancer cells - Northwestern Scholars', type='url_citation', url='https://www.scholars.northwestern.edu/en/publications/afap-110-is-required-for-actin-stress-fiber-formation-and-cell-ad/#:~:text=cytoskeletal%20tension%20through%20stress%20fiber,would%20promote%20focal%20adhesion%20formation')
118. AnnotationURLCitation(end_index=36599, start_index=36449, title='Actin filament-associated protein 1 is required for cSrc activity and secretory activation in the lactating mammary gland | Oncogene', type='url_citation', url='https://www.nature.com/articles/onc2014205#:~:text=binds%20to%20filamentous%20actin%20and,the%20lactating%20knockout%20mice%20were')
119. AnnotationURLCitation(end_index=36748, start_index=36600, title='Actin filament-associated protein 1 is required for cSrc activity and secretory activation in the lactating mammary gland | Oncogene', type='url_citation', url='https://www.nature.com/articles/onc2014205#:~:text=prostate%20cancer%20cells%2C%20AFAP1%20has,in%20lipid%20synthesis%20and%20the')
120. AnnotationURLCitation(end_index=37442, start_index=37252, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=Disruption%20of%20actin%20organization%20abrogates,evidence%20demonstrates%20the%20multifunctional%20roles')
121. AnnotationURLCitation(end_index=37605, start_index=37443, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=structures%20and%20disturbs%20integrin,bundling%20protein%2C%20is%20frequently')
122. AnnotationURLCitation(end_index=38079, start_index=37950, title='Actin filament-associated protein 1 is required for cSrc activity and secretory activation in the lactating mammary gland | Oncogene', type='url_citation', url='https://www.nature.com/articles/onc2014205#:~:text=Actin%20filament,an%20inability%20to%20nurse%20efficiently')
123. AnnotationURLCitation(end_index=38225, start_index=38080, title='Actin filament-associated protein 1 is required for cSrc activity and secretory activation in the lactating mammary gland | Oncogene', type='url_citation', url='https://www.nature.com/articles/onc2014205#:~:text=study%20also%20demonstrated%20that%20AFAP1,in%20the%20absence%20of%20AFAP1')
124. AnnotationURLCitation(end_index=38491, start_index=38378, title='Actin filament-associated protein 1 is required for cSrc activity and secretory activation in the lactating mammary gland | Oncogene', type='url_citation', url='https://www.nature.com/articles/onc2014205#:~:text=this%20study%2C%20we%20generated%20an,This')
125. AnnotationURLCitation(end_index=38886, start_index=38753, title='Actin filament-associated protein 1 is required for cSrc activity and secretory activation in the lactating mammary gland | Oncogene', type='url_citation', url='https://www.nature.com/articles/onc2014205#:~:text=production%20of%20%CE%B2,the%20apical%20surface%20of%20luminal')
126. AnnotationURLCitation(end_index=39217, start_index=39072, title='Actin filament-associated protein 1 is required for cSrc activity and secretory activation in the lactating mammary gland | Oncogene', type='url_citation', url='https://www.nature.com/articles/onc2014205#:~:text=study%20also%20demonstrated%20that%20AFAP1,in%20the%20absence%20of%20AFAP1')
127. AnnotationURLCitation(end_index=39374, start_index=39218, title='Actin filament-associated protein 1 is required for cSrc activity and secretory activation in the lactating mammary gland | Oncogene', type='url_citation', url='https://www.nature.com/articles/onc2014205#:~:text=activation%20in%20the%20cSrc%20knockout,the%20normal%20breast%2C%20specifically%20for')
128. AnnotationURLCitation(end_index=39766, start_index=39605, title='Actin filament-associated protein 1 is required for cSrc activity and secretory activation in the lactating mammary gland | Oncogene', type='url_citation', url='https://www.nature.com/articles/onc2014205#:~:text=activation%20in%20the%20cSrc%20knockout,breast%2C%20specifically%20for%20milk%20production')
129. AnnotationURLCitation(end_index=40175, start_index=39997, title='AFAP1 protein expression summary - The Human Protein Atlas', type='url_citation', url='https://v19.proteinatlas.org/ENSG00000196526-AFAP1#:~:text=Cancer%20prognostic%20summary%20Prognostic%20marker,actin%20filaments%20into%20both%20network')
130. AnnotationURLCitation(end_index=41717, start_index=41553, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=affects%20crosstalk%20between%20Src%20and,110%20resulted%20in%20decreased%20cell')
131. AnnotationURLCitation(end_index=41893, start_index=41718, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=prostatic%20hyperplasia%20but%20significantly%20increased,However%2C%20expression%20of%20an')
132. AnnotationURLCitation(end_index=42287, start_index=42123, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=affects%20crosstalk%20between%20Src%20and,110%20resulted%20in%20decreased%20cell')
133. AnnotationURLCitation(end_index=42690, start_index=42534, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=Downregulation%20of%20AFAP,critical%20for%20tumorigenic%20growth%2C%20in')
134. AnnotationURLCitation(end_index=42850, start_index=42691, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=models.%20Furthermore%2C%20downmodulation%20of%20AFAP,dependent%20mechanism')
135. AnnotationURLCitation(end_index=43120, start_index=42945, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=prostatic%20hyperplasia%20but%20significantly%20increased,However%2C%20expression%20of%20an')
136. AnnotationURLCitation(end_index=43521, start_index=43365, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=Downregulation%20of%20AFAP,critical%20for%20tumorigenic%20growth%2C%20in')
137. AnnotationURLCitation(end_index=43681, start_index=43522, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=models.%20Furthermore%2C%20downmodulation%20of%20AFAP,dependent%20mechanism')
138. AnnotationURLCitation(end_index=43993, start_index=43856, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=integrin%20%CE%B21%20expression,dependent%20mechanism')
139. AnnotationURLCitation(end_index=44346, start_index=44209, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=integrin%20%CE%B21%20expression,dependent%20mechanism')
140. AnnotationURLCitation(end_index=44457, start_index=44347, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=AFAP,dependent%20mechanism')
141. AnnotationURLCitation(end_index=44727, start_index=44590, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=integrin%20%CE%B21%20expression,dependent%20mechanism')
142. AnnotationURLCitation(end_index=44838, start_index=44728, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=AFAP,dependent%20mechanism')
143. AnnotationURLCitation(end_index=45564, start_index=45328, title='AFAP-110 is required for actin stress fiber formation and cell adhesion in MDA-MB-231 breast cancer cells - Northwestern Scholars', type='url_citation', url='https://www.scholars.northwestern.edu/en/publications/afap-110-is-required-for-actin-stress-fiber-formation-and-cell-ad/#:~:text=approach%20confirms%20that%20MDA,231%20breast%20cancer%20cell%20adhesion')
144. AnnotationURLCitation(end_index=45825, start_index=45565, title='AFAP-110 is required for actin stress fiber formation and cell adhesion in MDA-MB-231 breast cancer cells - Northwestern Scholars', type='url_citation', url='https://www.scholars.northwestern.edu/en/publications/afap-110-is-required-for-actin-stress-fiber-formation-and-cell-ad/#:~:text=cytoskeletal%20tension%20through%20stress%20fiber,would%20promote%20focal%20adhesion%20formation')
145. AnnotationURLCitation(end_index=46175, start_index=46017, title='Actin filament-associated protein 1 is required for cSrc activity and secretory activation in the lactating mammary gland | Oncogene', type='url_citation', url='https://www.nature.com/articles/onc2014205#:~:text=ability%20to%20alter%20actin%20filament,Cell%20Res%202000%3B%20255%3A%20102%E2%80%93113')
146. AnnotationURLCitation(end_index=46526, start_index=46368, title='Actin filament-associated protein 1 is required for cSrc activity and secretory activation in the lactating mammary gland | Oncogene', type='url_citation', url='https://www.nature.com/articles/onc2014205#:~:text=ability%20to%20alter%20actin%20filament,Cell%20Res%202000%3B%20255%3A%20102%E2%80%93113')
147. AnnotationURLCitation(end_index=46860, start_index=46670, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=Disruption%20of%20actin%20organization%20abrogates,evidence%20demonstrates%20the%20multifunctional%20roles')
148. AnnotationURLCitation(end_index=47023, start_index=46861, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=structures%20and%20disturbs%20integrin,bundling%20protein%2C%20is%20frequently')
149. AnnotationURLCitation(end_index=47528, start_index=47379, title='AFAP1 protein expression summary - The Human Protein Atlas', type='url_citation', url='https://v19.proteinatlas.org/ENSG00000196526-AFAP1#:~:text=Subcellular%20location,actin%20filaments%20into%20both%20network')
150. AnnotationURLCitation(end_index=47710, start_index=47529, title='AFAP1 protein expression summary - The Human Protein Atlas', type='url_citation', url='https://v19.proteinatlas.org/ENSG00000196526-AFAP1#:~:text=Cancer%20prognostic%20summary%20Prognostic%20marker,Low%20human%20brain%20regional%20specificity')
151. AnnotationURLCitation(end_index=48475, start_index=48311, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=activates%20cSrc%20through%20a%20direct,that%2C%20under%20conditions%20of%20cSrc')
152. AnnotationURLCitation(end_index=48620, start_index=48476, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=increase%20of%20AFAP,of%20input%20signals%2C%20in%20contrast')
153. AnnotationURLCitation(end_index=48873, start_index=48738, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=increase%20of%20AFAP,be%20used%20to%20predict%20the')
154. AnnotationURLCitation(end_index=49022, start_index=48874, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=cSrc%20and%20the%20formation%20of,be%20used%20to%20predict%20the')
155. AnnotationURLCitation(end_index=49457, start_index=49322, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=increase%20of%20AFAP,be%20used%20to%20predict%20the')
156. AnnotationURLCitation(end_index=49616, start_index=49458, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=that%20express%20enhanced%20levels%20of,110%20promotes%20cSrc%20activation')
157. AnnotationURLCitation(end_index=50056, start_index=49898, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=cSrc%20and%20the%20formation%20of,the%20response%20to%20targeted%20therapy')
158. AnnotationURLCitation(end_index=50234, start_index=50057, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=overexpression%2C%20the%20polymorphic%20variant%20of,the%20response%20to%20targeted%20therapy')
159. AnnotationURLCitation(end_index=51211, start_index=51066, title='AFAP1 - Drugs, Indications, Patents - Synapse', type='url_citation', url='https://synapse.patsnap.com/target/d0c14faf9cd134bcb3492bb97550290f#:~:text=Roles%20of%20AFAP1,and%20Urogenital%20System')
160. AnnotationURLCitation(end_index=52425, start_index=52274, title='LncRNA AFAP1-AS1 Modulates the Proliferation and Invasion of Gastric Cancer Cells by Regulating AFAP1 via miR-205-5p - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/34234560/#:~:text=Results%3A%20qPCR%20results%20showed%20that,Luciferase%20reporter%20gene')
161. AnnotationURLCitation(end_index=52580, start_index=52426, title='LncRNA AFAP1-AS1 Modulates the Proliferation and Invasion of Gastric Cancer Cells by Regulating AFAP1 via miR-205-5p - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/34234560/#:~:text=Moreover%2C%20miR,including%20proliferation%2C%20migration%20and%20invasion')
162. AnnotationURLCitation(end_index=52954, start_index=52791, title='LncRNA AFAP1-AS1 Modulates the Proliferation and Invasion of Gastric Cancer Cells by Regulating AFAP1 via miR-205-5p - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/34234560/#:~:text=differentiation%20%28p%3D0,including%20proliferation%2C%20migration%20and%20invasion')
163. AnnotationURLCitation(end_index=53109, start_index=52955, title='LncRNA AFAP1-AS1 Modulates the Proliferation and Invasion of Gastric Cancer Cells by Regulating AFAP1 via miR-205-5p - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/34234560/#:~:text=Moreover%2C%20miR,including%20proliferation%2C%20migration%20and%20invasion')
164. AnnotationURLCitation(end_index=53442, start_index=53317, title='LncRNA AFAP1-AS1 Modulates the Proliferation and Invasion of Gastric Cancer Cells by Regulating AFAP1 via miR-205-5p - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/34234560/#:~:text=Results%3A%20qPCR%20results%20showed%20that,5p')
165. AnnotationURLCitation(end_index=53597, start_index=53443, title='LncRNA AFAP1-AS1 Modulates the Proliferation and Invasion of Gastric Cancer Cells by Regulating AFAP1 via miR-205-5p - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/34234560/#:~:text=Moreover%2C%20miR,including%20proliferation%2C%20migration%20and%20invasion')
166. AnnotationURLCitation(end_index=54141, start_index=53992, title='AFAP1 - Drugs, Indications, Patents - Synapse', type='url_citation', url='https://synapse.patsnap.com/target/d0c14faf9cd134bcb3492bb97550290f#:~:text=01%20Mar%202024Current%20pharmaceutical%20design')
167. AnnotationURLCitation(end_index=54696, start_index=54551, title='AFAP1 - Drugs, Indications, Patents - Synapse', type='url_citation', url='https://synapse.patsnap.com/target/d0c14faf9cd134bcb3492bb97550290f#:~:text=Roles%20of%20AFAP1,and%20Urogenital%20System')
168. AnnotationURLCitation(end_index=55013, start_index=54868, title='AFAP1 - Drugs, Indications, Patents - Synapse', type='url_citation', url='https://synapse.patsnap.com/target/d0c14faf9cd134bcb3492bb97550290f#:~:text=Roles%20of%20AFAP1,and%20Urogenital%20System')
169. AnnotationURLCitation(end_index=56452, start_index=56310, title='AFAP1 - Drugs, Indications, Patents - Synapse', type='url_citation', url='https://synapse.patsnap.com/target/d0c14faf9cd134bcb3492bb97550290f#:~:text=01%20May%202024JCO%20precision%20oncology')
170. AnnotationURLCitation(end_index=57678, start_index=57520, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=cSrc%20and%20the%20formation%20of,the%20response%20to%20targeted%20therapy')
171. AnnotationURLCitation(end_index=59390, start_index=59212, title='AFAP1 protein expression summary - The Human Protein Atlas', type='url_citation', url='https://v19.proteinatlas.org/ENSG00000196526-AFAP1#:~:text=Cancer%20prognostic%20summary%20Prognostic%20marker,actin%20filaments%20into%20both%20network')
172. AnnotationURLCitation(end_index=59604, start_index=59446, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=cSrc%20and%20the%20formation%20of,the%20response%20to%20targeted%20therapy')
173. AnnotationURLCitation(end_index=59959, start_index=59791, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=first%20identified%20as%20a%20substrate,prostate%20cancer%20cells%20inhibited%20cell')
174. AnnotationURLCitation(end_index=60089, start_index=59960, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=AFAP,as%20phospholipids%20at%20the%20cellular')
175. AnnotationURLCitation(end_index=60561, start_index=60447, title='The actin filament-associated protein AFAP-110 is an adaptor protein that modulates changes in actin filament integrity | Oncogene', type='url_citation', url='https://www.nature.com/articles/1204784#:~:text=AFAP,to%20alter%20actin%20filament%20integrity')
176. AnnotationURLCitation(end_index=60802, start_index=60642, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=Scholar%20scholar.google.com%20%5D%20,directed%20activation%20of%20cSrc%20by')
177. AnnotationURLCitation(end_index=60986, start_index=60858, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=,0148.%20%5BDOI%5D%20%5BPMC%20free%20article')
178. AnnotationURLCitation(end_index=61221, start_index=61044, title='AFAP-110 is required for actin stress fiber formation and cell adhesion in MDA-MB-231 breast cancer cells - Northwestern Scholars', type='url_citation', url='https://www.scholars.northwestern.edu/en/publications/afap-110-is-required-for-actin-stress-fiber-formation-and-cell-ad/#:~:text=AFAP,Although')
179. AnnotationURLCitation(end_index=61403, start_index=61280, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=AFAP,motifs%20are%20involved%20in%20the')
180. AnnotationURLCitation(end_index=61533, start_index=61404, title='AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1978423/#:~:text=AFAP,proteins%2C%20such%20as%20the%20receptor')
181. AnnotationURLCitation(end_index=61747, start_index=61583, title='A Polymorphic Variant of AFAP-110 Enhances cSrc Activity - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2915419/#:~:text=activates%20cSrc%20through%20a%20direct,that%2C%20under%20conditions%20of%20cSrc')
182. AnnotationURLCitation(end_index=61944, start_index=61799, title='Actin filament-associated protein 1 is required for cSrc activity and secretory activation in the lactating mammary gland | Oncogene', type='url_citation', url='https://www.nature.com/articles/onc2014205#:~:text=study%20also%20demonstrated%20that%20AFAP1,in%20the%20absence%20of%20AFAP1')
183. AnnotationURLCitation(end_index=62101, start_index=61945, title='Actin filament-associated protein 1 is required for cSrc activity and secretory activation in the lactating mammary gland | Oncogene', type='url_citation', url='https://www.nature.com/articles/onc2014205#:~:text=activation%20in%20the%20cSrc%20knockout,the%20normal%20breast%2C%20specifically%20for')
184. AnnotationURLCitation(end_index=62397, start_index=62234, title='LncRNA AFAP1-AS1 Modulates the Proliferation and Invasion of Gastric Cancer Cells by Regulating AFAP1 via miR-205-5p - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/34234560/#:~:text=differentiation%20%28p%3D0,including%20proliferation%2C%20migration%20and%20invasion')

Actin Filament-Associated Protein 1 (AFAP1): Structure, Function, and Cellular Mechanisms

AFAP1 (actin filament-associated protein 1), also known as AFAP-110, is a multifunctional adapter protein that plays critical roles in regulating cytoskeletal dynamics and cellular signaling, particularly through its interactions with the Src family tyrosine kinases and filamentous actin structures[1][4]. Recent research has revealed that AFAP1 functions as a dual-role regulator, operating both as a direct mediator of signal transduction at the protein level and indirectly through its associated antisense long noncoding RNA (AFAP1-AS1), which modulates oncogenic processes in various cancer types[9][14]. The protein is primarily localized to actin filaments, focal adhesions, and specialized membrane structures called podosomes and invadopodia, where it coordinates the assembly and remodeling of actin-rich structures essential for cell adhesion, migration, and invasion[1][12][19]. This comprehensive report examines the molecular architecture, biochemical functions, cellular mechanisms, and biological significance of AFAP1, synthesizing current knowledge from structural biology, cell biology, and cancer research to provide an integrated understanding of this important regulatory protein.

Molecular Architecture and Domain Organization

AFAP1 possesses a highly specialized modular architecture that enables its diverse cellular functions through multiple protein-protein interaction domains. The protein structure includes two Pleckstrin Homology (PH) domains, which are characteristic features of the broader AFAP family of proteins and serve as recognition modules for phosphorylated lipids and protein interaction surfaces[54][55]. One of these PH domains contains a binding site for protein kinase C (PKC), specifically PKCα, which phosphorylates serine residue 277 and plays a critical role in regulating AFAP1's ability to modulate podosome formation and stability[49][52][54]. Beyond the PH domains, AFAP1 contains N-terminal SH2 and SH3 binding motifs that specifically interact with the SH3 and SH2 domains of the nonreceptor tyrosine kinase c-Src, enabling tight coupling of AFAP1 to Src family kinase signaling[6][10][54]. These SH3 binding motifs are structurally conserved and essential for stable complex formation with Src and subsequent tyrosine phosphorylation of AFAP1[50]. The C-terminal region of the protein harbors actin-binding domains that mediate direct interactions with filamentous actin (F-actin) and likely involve AFAP1 multimeric assemblies, allowing the protein to cross-link actin filaments into both network and bundle structures[1][40][54][55]. The N-terminal SH3 binding motif is absolutely critical for AFAP1 function, as mutations or deletions of this motif completely abolish both Src binding and the ability of AFAP1 to regulate downstream cellular processes[1][6][10].

The protein exists in at least two isoforms, the neuronal cell-specific A isoform and the ubiquitously expressed B isoform, suggesting specialized functions in different cellular contexts[33]. Multiple transcript variants have been identified that encode different AFAP1 isoforms, providing additional regulatory flexibility through alternative splicing[1][4][8]. The overall design of AFAP1's domain organization—combining PKC regulatory sites, Src interaction motifs, and actin-binding capability—positions it as an ideal scaffold protein capable of integrating multiple signaling inputs to coordinate actin cytoskeletal responses. This architecture is shared to varying degrees by other family members such as AFAP1L1 and AFAP1L2 (also known as XB130), though subtle differences in domain structure and amino acid sequences lead to different subcellular localizations and binding affinities for specific interaction partners[57].

Protein-Protein Interactions and Src Kinase Coupling

The interaction between AFAP1 and the proto-oncogene tyrosine-protein kinase Src (c-Src) represents one of the most fundamental and well-characterized aspects of AFAP1 biology, as this coupling directly translates extracellular signals into cytoskeletal reorganization. AFAP1 binds to c-Src through its N-terminal SH3 binding motif, which interacts with the SH3 domain of Src, and this interaction is further strengthened by phosphorylation-dependent binding of the Src SH2 domain to tyrosine-phosphorylated residues on AFAP1[6][22][51]. Upon phosphorylation by activated Src (or by PKCα), AFAP1 undergoes conformational changes that expose additional interaction surfaces, allowing the SRC SH2 domain to bind phosphorylated tyrosine residues on AFAP1, thereby stabilizing and potentially increasing the catalytic efficiency of the AFAP1-Src complex[22][47][51]. This phosphorylation-dependent interaction is particularly important for the localization of Src to actin filaments, as AFAP1 serves as a bridging molecule that brings activated Src into proximity with its substrate targets in the actin cytoskeleton[22][47][51]. AFAP1 is itself a substrate for both PKCα and Src family kinases (c-Src and Fyn), creating a regulatory feedback loop in which AFAP1 phosphorylation enhances Src activation and vice versa[13][54][37]. In response to stimuli such as prolactin in mammary gland tissue, AFAP1 becomes tyrosine phosphorylated and forms a stable complex with c-Src, facilitating normal spatial and temporal Src activity[54].

The relationship between AFAP1 and Src extends beyond simple binding, as AFAP1 can directly activate c-Src through interactions with both the SH3 and SH2 domains, suggesting that AFAP1 acts as a nucleation factor or scaffold that promotes Src autophosphorylation and activation[7][16]. Mechanistic studies indicate that AFAP1 can facilitate c-Src activation through binding-induced conformational changes that relieve autoinhibition of the kinase[7][16]. The C-terminal actin-binding capability of AFAP1 means that once activated, the AFAP1-Src complex is simultaneously positioned on actin filaments where Src can phosphorylate additional substrates involved in cytoskeletal organization[40][54]. This spatial organization is crucial because Src phosphorylates numerous substrates beyond AFAP1, including cortactin and other actin regulatory proteins, all of which need to be coordinated to produce coherent changes in cytoskeletal architecture[22][47]. Interestingly, AFAP1 appears to show substrate specificity or preference in terms of which Src family kinases it interacts with most efficiently—while it binds strongly to c-Src via its SH3 binding motif, AFAP1L1, a family member, shows reduced affinity for Src but instead preferentially associates with cortactin, indicating functional diversification within the AFAP family[45][57].

Cellular Localization and Subcellular Distribution

AFAP1 exhibits a highly dynamic and stimulus-dependent pattern of subcellular localization that reflects its functional role in organizing actin-based cellular structures. In unstimulated cells, AFAP1 localizes prominently to actin filaments and focal adhesion sites, where it remains available to respond to cellular signals[23][59]. The protein is primarily distributed along the cytoskeleton, localizing to the cell cortex and to the ventral surface of cells where focal adhesions and podosomes form[1][59]. Upon stimulation with activators of PKC or in response to growth factors, AFAP1 rapidly translocates to newly forming podosomes and invadopodia, specialized actin-rich membrane protrusions that are sites of intense cytoskeletal remodeling[17][54][56]. In the lactating mammary gland, AFAP1 shows a striking pattern of localization at the apical surface of luminal epithelial cells, where it colocalizes with active c-Src, particularly during early lactation when elevated Src activity is required for proper milk protein secretion[54]. The protein outlines the cellular cortex with equal distribution on basolateral and apical sides of cells, localized exterior to cytokeratin staining, suggesting its role in organizing cortical actin structures that are fundamental to epithelial cell architecture and function[54].

AFAP1's ability to respond dynamically to signals is reflected in its redistribution to sites of active actin remodeling. Upon c-Src binding and activation, AFAP1 and c-Src move together to podosomes, which are adhesion structures found on the ventral membrane of cells containing an F-actin-rich core surrounded by adhesion proteins[17][56]. This coordinated localization is essential for AFAP1's function in regulating podosome assembly and stability, as the protein must be present at the site of actin dynamics to exert its mechanical effects on filament organization[16][37]. In specialized cell types such as retinal ganglion cells, AFAP1 is expressed and likely plays roles in ocular physiology, with expression variants suggesting involvement in tissue-specific functions[33][36]. The dynamic nature of AFAP1 localization—shifting from baseline distribution on focal adhesions and actin filaments to concentrated accumulation at podosomes and invadopodia in response to specific signals—demonstrates that AFAP1 functions as a signal-responsive organizer of cytoskeletal structures rather than as a static structural component.

Regulation of Actin Filament Structure and Mechanical Properties

At the molecular level, AFAP1 directly modulates the physical properties of the actin cytoskeleton through its dual capacity to bind both Src kinase and F-actin, creating what is essentially a mechanochemical coupling system. AFAP1 can cross-link actin filaments into both network and bundle structures, a function that requires both its actin-binding domain and potentially its capacity for self-association through multimerization[55][58]. The actin-binding domain of AFAP1, located at the C-terminus, is critical for regulating actin filament structure, and overexpression of deletion mutants lacking the actin-binding domain (AFAPΔABD) results in disrupted regulation of actin organization[43]. Phosphorylation of serine 277 by PKCα increases the ability of AFAP1 to cross-link actin filaments, suggesting that post-translational modification directly enhances the mechanical interaction between AFAP1 and the actin cytoskeleton[49][54]. The mechanism by which AFAP1 affects actin filament integrity appears to involve not merely passive cross-linking, but also active regulation of actin filament dynamics, as AFAP1 can modulate the responsiveness of actin networks to external mechanical forces and cellular signaling inputs[43].

The functional significance of AFAP1's actin-binding activity is particularly evident in its role in actin stress fiber formation and maintenance. AFAP1 plays an important role in breast cancer cell adhesion, possibly by regulating stress filament cross-linking, which would promote focal adhesion maturation and mechanotransduction signaling[41]. Loss or reduction of AFAP1 expression results in decreased actin stress fiber formation and loss of cell stress filament integrity, indicating that AFAP1 is a critical positive regulator of stress fiber assembly[21][38]. In nasopharyngeal carcinoma cells, loss of lncRNA AFAP1-AS1 (which is transcribed from the antisense strand and acts partly through AFAP1-independent mechanisms) results in loss of stress fiber formation via effects on F-actin polymerization, though the exact relationship to AFAP1 protein levels remains to be clarified[42][60]. The mechanism appears to involve AFAP1's ability to stabilize actin filament bundles through cross-linking and possibly through recruitment of additional actin regulatory proteins via its interaction with c-Src and other signaling molecules. AFAP1 may thus represent a key node in the complex regulatory network that balances actin polymerization with filament stabilization and organization into higher-order structures.

Podosomes: Formation, Regulation, and Function

Podosomes represent specialized actin-based cellular structures where AFAP1 plays a particularly prominent role in orchestrating assembly and regulating the maturation and turnover of these dynamic organelles. Podosomes are adhesion structures found on the ventral membrane of cells and consist of a core of cross-linked F-actin surrounded by a ring of adhesion-related proteins including vinculin, paxillin, and talin[1][17][26][29]. AFAP1 is absolutely required to mediate PKCα-induced activation of the tyrosine kinase c-Src and the subsequent formation of podosomes, as demonstrated through studies showing that AFAP1 null cells fail to form podosomes in response to PKC activation[16][37]. The mechanism involves PKCα phosphorylation of AFAP1 at serine 277, which enhances AFAP1's ability to activate c-Src, and the resulting activated AFAP1-Src complex localizes to sites of incipient podosome formation where it phosphorylates downstream substrates[16][49][54].

The formation of podosomes occurs in a stepwise manner, with the first visible stage being the formation of actin puncta, small accumulations of branched actin filaments at specific locations[26][29]. AFAP1 appears to be involved in the early stages of this process through its interaction with c-Src and actin filaments, likely helping to stabilize initial actin accumulations and recruit additional proteins required for podosome maturation[17][26]. Following formation of the actin puncta, adhesion proteins including vinculin and paxillin are recruited to form a ring-like structure surrounding the actin core[26][29]. The adhesion ring that forms around podosomes represents a specialized focal adhesion-like structure that serves to anchor the podosome to the underlying extracellular matrix and likely couples mechanical forces from the actin core to adhesion signaling pathways[26]. AFAP1 regulates not only the formation of podosomes but also their stability and turnover—studies have shown that AFAP1 phosphorylation by PKCα plays a role in regulating podosome formation and lifespan, suggesting that AFAP1-mediated signaling directly controls the temporal dynamics of podosome assembly and disassembly[49][52].

Both c-Src and the associated phosphatase PTP1B are required for proper podosome dynamics and turnover, with CSK (a negative regulator of Src) also playing a regulatory role[29]. This indicates that AFAP1, as the primary mechanism through which PKC activates Src for podosome formation, is embedded within a broader regulatory network that balances activation and inactivation signals to produce the appropriate temporal pattern of podosome formation and regression. In certain cell types such as vascular smooth muscle cells treated with phorbol esters or Src-transformed fibroblasts, podosomes form rapidly (in less than 15 minutes) from disassembling focal adhesions, with AFAP1 and c-Src activity being central to this transition[29]. This direct transformation of focal adhesions into podosomes suggests that AFAP1 participates in a structural remodeling process that converts one actin-based adhesion structure into another, a process that would require simultaneous cross-linking of new actin assemblies while disrupting existing ones.

Invadopodia: Invasive Structures and Cancer Cell Invasion

Beyond its role in podosome formation, AFAP1 participates in the assembly and regulation of invadopodia, which are F-actin-rich membrane protrusions that breach basement membrane barriers during cell invasion[39][42]. Invadopodia differ from podosomes in that they are particularly prominent in cancer cells with high metastatic potential and function primarily as degradative structures rather than adhesion organelles, though they share many molecular components including actin filaments, adhesion molecules, and regulatory proteins[26][29][39]. The formation of invadopodia, like podosomes, requires integration of growth factor signaling and adhesion signaling, with different stages of invadopodium maturation being regulated by distinct signaling inputs[26]. AFAP1 has been shown to regulate cellular responses requiring actin cytoskeletal changes such as adhesion, invadopodia formation, and invasion in breast and prostate cancer cells[5][12]. The precise role of AFAP1 in invadopodia formation and function appears to parallel its role in podosomes, with AFAP1 and c-Src working together to organize F-actin core structures and recruit associated proteins.

The functional consequence of AFAP1-mediated invadopodium assembly is enhanced capacity for extracellular matrix degradation and cellular invasion. Invadopodia contain matrix metalloproteinases (particularly MT1-MMP) that are localized to the ventral membrane and oriented toward the extracellular matrix where they perform localized proteolysis[26][39]. The stability of MT1-MMP at invadopodia is promoted by direct interaction with invadopodial F-actin, providing a direct linkage between the actin core organized by AFAP1 and other proteins, and the proteolytic machinery that actually degrades matrix[39][26]. The assembly of invadopodia occurs in stages, with growth factor signaling (particularly PI3K signaling) promoting initial formation, while adhesion to the extracellular matrix promotes maturation and localized protease exocytosis, resulting in a functional degrading structure[26]. AFAP1's role in organizing the actin core that forms the structural foundation of invadopodia thus directly enables matrix degradation and cellular invasion, providing a molecular mechanism linking cytoskeletal organization to the invasive phenotype of cancer cells.

Signaling Integration: PKCα, Integrin Signaling, and FAK

AFAP1 functions as a critical integrator of multiple signaling pathways, most notably receiving input from protein kinase C (PKCα) and transducing signals through c-Src to organize actin cytoskeletal responses. PKCα activates AFAP1 through phosphorylation of serine 277, which enhances AFAP1's ability to bind and activate c-Src[49][54]. This PKC-AFAP1-Src axis is particularly important in response to phorbol esters, which are natural PKC activators, and in response to growth factors that activate PKC through phospholipase C-mediated generation of diacylglycerol[54]. Beyond PKCα input, AFAP1 receives signals through integrin-mediated adhesion, as integrin ligation to the extracellular matrix activates Src through FAK (focal adhesion kinase), and activated c-Src in turn phosphorylates AFAP1[54]. The result is that AFAP1 becomes a convergence point for signals emanating from both growth factor receptors (via PKC) and integrin receptors (via Src), allowing cells to coordinate cytoskeletal changes that occur in response to both growth-promoting and adhesion signals.

AFAP1 also appears to participate in the regulation of focal adhesion dynamics and turnover, though this function is less completely characterized than its roles in podosomes and invadopodia. Src-mediated phosphorylation of FAK at multiple tyrosine residues is necessary to enhance the adaptor function of FAK and promote focal adhesion turnover through calpain-mediated proteolysis[44]. Since AFAP1 serves as a primary activator of Src in response to PKC, AFAP1 indirectly regulates focal adhesion turnover through this mechanism. Moreover, AFAP1's direct interaction with actin filaments means that it can modulate the mechanical coupling between focal adhesions and the actin cytoskeleton, potentially influencing the contractile forces that stabilize focal adhesions or the mechanical transitions that occur during focal adhesion disassembly. In the context of PKC activation with phorbol esters, focal adhesions dissolve and then reorganize around newly formed actin puncta that will become podosomes, suggesting that AFAP1-mediated cytoskeletal remodeling directly drives the transition between focal adhesion and podosome architecture[26][29].

The AFAP1-AS1 Long Noncoding RNA: Oncogenic Regulation of Cytoskeletal Dynamics

In parallel with the protein-level functions of AFAP1, a long noncoding RNA (lncRNA) transcribed from the antisense strand of the AFAP1 gene locus, termed AFAP1-AS1 (or AFAP1-AS in earlier literature), has emerged as a critical regulator of cancer progression and metastasis. AFAP1-AS1 localizes to the antisense genomic DNA strand near the C-terminus of AFAP1, at the actin binding domain of AFAP1, and is transcribed as an independent RNA molecule[2][21]. The long noncoding RNA functions primarily through competing endogenous RNA (ceRNA) mechanisms, in which AFAP1-AS1 contains multiple binding sites for microRNAs and functions as a "molecular sponge" that sequesters miRNAs and prevents them from binding to and suppressing their target messenger RNAs[2][21]. In the context of Hirschsprung disease (a developmental disorder affecting neural crest cell migration), AFAP1-AS was found to be downregulated compared to normal tissues, and knockdown of AFAP1-AS inhibited neural crest cell proliferation and migration by competitively binding miR-181a and thereby allowing increased expression of RAP1B[2][21]. This ceRNA regulatory network (AFAP1-AS/miR-181a/RAP1B) demonstrates that the lncRNA participates in the regulation of neural crest cell colonization, a process fundamentally dependent on cell migration and cytoskeletal dynamics[2][21].

However, in the context of cancer, AFAP1-AS1 is typically upregulated and functions as an oncogene promoting tumor progression. Overexpression of AFAP1-AS1 is associated with enhanced cell proliferation, migration, invasion, epithelial-mesenchymal transition (EMT), and metastasis, thereby correlating with poor clinical outcomes across multiple cancer types[9][14][25][36][38]. AFAP1-AS1 has been found to be abnormally expressed in numerous cancers, including cholangiocarcinoma, pancreatic adenocarcinoma, non-small cell lung cancer, nasopharyngeal carcinoma, breast cancer, osteosarcoma, gastric cancer, esophageal squamous cell carcinoma, colorectal cancer, and prostate cancer[25][36][38][9]. In non-small cell lung cancer (NSCLC), AFAP1-AS1 enhances migration and invasive properties through activation of IRF7 and the RIG-I-like receptor signaling pathway, and also interacts with the epigenetic regulator EZH2 to repress expression of the cell cycle inhibitor p21[38]. In breast cancer, particularly in triple-negative breast cancer (TNBC), AFAP1-AS1 sequences miR-145 to allow increased expression of MTH1, thereby enhancing proliferation and invasiveness[38]. The lncRNA also sequesters miR-2110 in breast cancer cells, leading to enhanced expression of the transcription factor Sp1[38].

Remarkably, in breast cancer cells resistant to the therapeutic antibody trastuzumab (Herceptin), AFAP1-AS1 can be secreted into exosomes and transmitted to other cells, where it induces trastuzumab resistance through interaction with the RNA-binding protein AUF1 and subsequent induction of ERBB2 (also known as HER2) translation[38]. This exosomal transmission of AFAP1-AS1 represents a novel form of intercellular communication in cancer, where the lncRNA can disseminate therapy resistance to other cancer cells in the tumor microenvironment[15]. In osteosarcoma, AFAP1-AS1 promotes tumorigenesis through the RhoC/ROCK1/p38MAPK/Twist1 cascade, and can sequester miR-497 and miR-4695-5p, thereby increasing expression of IGF1R and TCF4, which activate Wnt-β catenin signaling[38]. In gastric cancer, AFAP1-AS1 promotes proliferation and metastasis through sequestration of miR-155-5p, leading to enhanced expression of FGF7[38]. The mechanistic studies indicate that AFAP1-AS1 modulates actin filament integrity by influencing the expression of key molecules in cytoskeletal regulation and can affect the protein level of its sense counterpart, AFAP1, either directly or via interactions with regulatory factors such as EZH2 and SNIP1[9][14].

Importantly, studies in animal models (particularly BALB/c nude mice) have verified the oncogenic roles of AFAP1-AS1 in different cancer types, with knockdown of AFAP1-AS1 consistently leading to significant reduction in tumor size and weight, attenuation of tumor growth rate, and enhancement of response to therapeutic modalities[38]. In NSCLC, AFAP1-AS1 silencing not only reduces tumorigenicity but also confers chemosensitivity[38]. In breast cancer, AFAP1-AS1 downregulation can reduce trastuzumab resistance, suggesting therapeutic potential for targeting this lncRNA[38]. The cellular localization of AFAP1-AS primarily to the cytoplasm indicates that it functions through interaction with miRNAs and mRNA regulation rather than nuclear transcriptional regulation[2][21]. Loss of stress fiber formation in cells with reduced AFAP1-AS1 expression suggests that the lncRNA somehow influences actin dynamics, possibly through mechanisms involving AFAP1 protein or through direct effects on expression of actin regulatory proteins via its ceRNA activities[2][21][42][60].

Genetic Variation and Disease Association

Population-based genetic studies have identified associations between variants in the AFAP1 gene locus and common human diseases, particularly primary open-angle glaucoma, the most common form of glaucoma and a leading cause of blindness worldwide. A genome-wide association study identified a SNP (rs4619890) within the AFAP1 gene that confers risk of primary open-angle glaucoma, with the associated SNP rs28495790 (in high linkage disequilibrium with rs4619890) likely affecting binding of proteins such as CTCF and RAD21, and altering the sequence of regulatory motifs for binding of several proteins including PAX6[33]. The functional mechanism underlying the association appears to involve AFAP1's role in regulating the actin cytoskeleton in ocular tissues, as actin cytoskeleton-modulating signals have been demonstrated to be involved in the regulation of aqueous outflow and intraocular pressure, which are critical parameters in glaucoma pathogenesis[33]. AFAP1 is expressed in retinal ganglion cells (the cells that undergo apoptosis in glaucoma), as well as in the trabecular meshwork, retina, optic nerve, and optic nerve head[33]. Both the neuronal A isoform and the ubiquitously expressed B isoform of AFAP1 are detected in human retinal tissue, with the B isoform more broadly distributed in ocular tissues including iris, ciliary body, lens, optic nerve, and optic nerve head[33].

The involvement of AFAP1 in glaucoma likely reflects its function in regulating actin dynamics and cell morphology in tissues critical for maintaining normal intraocular pressure. In the trabecular meshwork, which controls aqueous humor outflow, AFAP1-mediated regulation of the actin cytoskeleton may influence cell shape and the spacing of trabecular meshwork cells, thereby affecting fluid filtration capacity. In retinal ganglion cells, AFAP1 may regulate axonal morphology and cell survival through its effects on cytoskeletal organization. The association between AFAP1 variants and glaucoma risk provides strong evidence that normal AFAP1 function is important for maintaining ocular homeostasis, and furthermore suggests that AFAP1-based therapeutic approaches might be relevant to glaucoma treatment, though this remains speculative at present.

Tissue Expression and Specialized Cell Types

AFAP1 shows a broad but selective pattern of expression across human tissues, with particularly high expression in tissues with significant cytoskeletal dynamics and specialized cellular structures. Analysis of gene expression data reveals that AFAP1 is expressed in numerous tissues including nervous system tissues (hippocampal formation, amygdala, basal ganglia, midbrain, spinal cord, cerebral cortex, cerebellum, hypothalamus, retina), endocrine tissues (thyroid gland, parathyroid gland, adrenal gland, pituitary gland), gastrointestinal tissues (esophagus, stomach, duodenum, small intestine, rectum, colon), hepatic tissues (liver, gallbladder), urinary tissues (kidney, urinary bladder), reproductive tissues (testis, epididymis, prostate, seminal vesicle, vagina, breast, cervix, endometrium, fallopian tube, ovary), and cardiovascular tissues (heart muscle, blood vessels)[23][28][59]. AFAP1 expression in specialized cell types such as retinal ganglion cells suggests its involvement in ocular physiology and possibly in the pathogenesis of glaucoma, as mentioned above[9][14][33][36].

The ubiquitous expression pattern of at least the AFAP1 B isoform across tissues suggests that AFAP1 performs fundamental functions in actin cytoskeletal organization that are required in virtually all cell types. However, the existence of the neuronal A isoform and the selective expression of AFAP1 in particular tissues like retinal ganglion cells indicates that specialized variants of AFAP1 may be required for tissue-specific functions. The expression profile of AFAP1 in tissues with high cellular motility, adhesion dynamics, or specialized membrane structures (such as the nervous system and reproductive tissues) is consistent with its proposed roles in regulating actin-based adhesion and migration. In the context of cancer, AFAP1 expression is often elevated in tumor tissues compared to normal tissue, and in some cases expression level predicts clinical outcomes, as demonstrated for AFAP1L1 in colorectal cancer[20][45][48].

The AFAP1 Family: Structural Relationships and Functional Diversification

AFAP1 is the prototype member of a family of actin filament-associated proteins that includes AFAP1L1 and AFAP1L2 (also termed XB130), with all three members sharing similar modular domain structures containing PH domains and SH2/SH3 binding motifs for Src interaction[57]. However, despite this structural similarity, the AFAP family members show important differences in subcellular localization, binding partner specificity, and cellular functions. AFAP1 binds strongly to c-Src via its SH3 binding motif and shows prominent localization to focal adhesions and podosomes[1][10][54][56]. AFAP1L1, in contrast, does not bind strongly to Src but instead preferentially associates with cortactin and colocalizes with cortactin within invadopodia[20][45][48]. AFAP1L1 was identified as a metastasis-predicting marker for spindle cell sarcomas and has been found to be elevated in colorectal cancer tissues, where high expression serves as an independent factor predicting recurrence of rectal cancers[20][45][48]. AFAP1L1-expressing cells exhibit increased motility, enhanced invasion, resistance to anoikis (death upon loss of cell-matrix contact), and accelerated tumor growth in vivo[20][45]. The localization of AFAP1L1 to the ringed structure of invadopodia together with vinculin indicates that AFAP1L1 forms novel complexes distinct from those formed by AFAP1[20][45][48].

AFAP1L2/XB130 appears to have additional functions not shared by AFAP1 or AFAP1L1, including involvement in growth factor signaling and cell survival pathways. The existence of this family of proteins with related structures but divergent binding partners and functions suggests that the AFAP family evolved to provide specialized adaptor functions in different cellular compartments and in response to different signaling pathways. Notably, AFAP1L1 interacts with vinculin, a major focal adhesion protein, through novel mechanisms that appear to disrupt normal focal adhesion architecture and promote cell invasion and EMT[20][45][48]. This diversification within the AFAP family may reflect an evolutionary strategy to enable flexible regulation of different aspects of cell adhesion and migration in different cellular contexts. The structural similarity but functional divergence of AFAP family members underscores the principle that protein domains and interaction motifs can be combined in modular fashion to generate proteins with distinct cellular functions.

Summary of Key Biological Processes and Functions

AFAP1 participates in multiple interconnected biological processes that collectively enable cells to dynamically modulate their adhesion and migratory behavior in response to environmental and developmental signals. At the molecular level, AFAP1 functions as a scaffolding protein that couples signals from activated protein kinase C and Src family kinases to the actin cytoskeleton, thereby promoting formation of actin-based structures including stress fibers, focal adhesions, podosomes, and invadopodia[9][12][14][54]. These structures are essential for fundamental cellular processes including cell adhesion, spreading, migration, and invasion. In the context of normal physiology, AFAP1 likely participates in developmental processes requiring coordinated cell migration, such as neural crest cell migration and vascular development, and also in maintaining cellular functions in differentiated tissues such as the mammary gland during lactation[54]. In the context of cancer, elevated AFAP1 expression and enhanced activity of the AFAP1-AS1 lncRNA promote the metastatic potential of cancer cells by enhancing migration, invasion, and cellular plasticity through epithelial-mesenchymal transition[9][14][25][36][38].

The physiological regulation of AFAP1 involves both post-translational modification of the AFAP1 protein itself and transcriptional/post-transcriptional regulation of expression through both the AFAP1 gene and the AFAP1-AS1 lncRNA. PKCα-mediated phosphorylation at serine 277 enhances AFAP1's ability to bind and activate Src, while tyrosine phosphorylation by Src itself stabilizes the AFAP1-Src complex through SH2 domain engagement[49][54]. The expression of AFAP1 is modulated in response to developmental signals and in cancers, with elevated expression generally associated with enhanced invasive and migratory potential. The AFAP1-AS1 lncRNA, which can either promote or suppress cancer depending on the specific cancer context, functions primarily as a ceRNA that regulates the availability of microRNAs and thus modulates expression of microRNA target genes[2][9][14][21][36][38]. This multilevel regulation—encompassing transcriptional control of both AFAP1 and AFAP1-AS1, post-translational modification of AFAP1 protein, and post-transcriptional control via AFAP1-AS1 ceRNA activity—enables precise spatial and temporal control of AFAP1-mediated cytoskeletal responses.

Clinical and Therapeutic Implications

The identification of AFAP1 and AFAP1L1 as factors promoting cancer progression has led to consideration of these proteins as potential therapeutic targets. In animal models (BALB/c nude mice), local administration of short interfering RNA (siRNA) targeting AFAP1L1 significantly suppressed tumor growth of colorectal cancer xenografts, suggesting the feasibility of targeting AFAP1 family members therapeutically[20][45][48]. Similarly, knockdown of AFAP1-AS1 in various cancer models consistently reduces tumorigenicity and can enhance chemosensitivity[38]. However, the essential roles of AFAP1 in normal cellular processes including adhesion, migration, and cytoskeletal organization necessitate careful consideration of toxicity to normal tissues if AFAP1 were to be targeted therapeutically. The tissue-restricted expression of the AFAP1 A isoform in neurons suggests that complete inhibition of AFAP1 function might not be tolerated in the nervous system, whereas AFAP1L1 targeting might be more selectively toxic to cancer cells if AFAP1L1 expression is elevated in tumors but remains low in normal tissues.

The association between AFAP1 variants and glaucoma risk opens the possibility of developing AFAP1-based therapies for glaucoma management, potentially by modulating AFAP1 activity or expression to enhance actin cytoskeletal dynamics in trabecular meshwork cells and thereby improve aqueous humor outflow[33]. The finding that AFAP1-AS1 is secreted in exosomes and can disseminate trastuzumab resistance in breast cancer suggests that blocking exosomal AFAP1-AS1 or its cellular uptake might represent a novel therapeutic strategy to prevent therapy resistance in cancer[15][38]. However, therapeutic approaches targeting AFAP1 or AFAP1-AS1 remain largely preclinical and would require substantial development before clinical application. Future research should focus on understanding tissue-specific functions of AFAP1 to identify contexts in which AFAP1 inhibition would be beneficial with acceptable toxicity, and on developing selective inhibitors of AFAP1-Src interaction or AFAP1-mediated cytoskeletal reorganization that might have therapeutic utility.

Future Directions and Outstanding Questions

Despite substantial progress in understanding AFAP1 biology, significant questions remain regarding the precise mechanisms of actin cross-linking and filament organization by AFAP1, the detailed structural basis for AFAP1 interactions with Src and actin, and the complete spectrum of AFAP1 functions in normal physiology. The three-dimensional crystal structure of AFAP1, particularly in complex with c-Src and actin filaments, would provide crucial insights into the molecular details of AFAP1's catalytic mechanisms and its role in organizing actin-based structures. The relative roles of AFAP1-mediated Src activation versus AFAP1's direct actin cross-linking activity in promoting different cellular processes remain incompletely understood, and future studies using mutants specifically defective in either Src binding or actin binding might clarify these distinct contributions. The mechanisms by which AFAP1-AS1 lncRNA regulates AFAP1 protein expression, either directly or indirectly through its various ceRNA interactions, warrant further investigation, as does the question of whether there are direct interactions between AFAP1 protein and AFAP1-AS1 RNA. The tissue-specific and developmental stage-specific functions of the AFAP1 A and B isoforms require deeper investigation, particularly in the context of nervous system development and function.

The relationship between AFAP1 function and other actin regulatory pathways, particularly those involving Arp2/3 complex, mDia formin family proteins, and cofilin-mediated actin depolymerization, remains incompletely characterized despite clear functional connections in the literature. The coordination of AFAP1-mediated signaling with growth factor signaling pathways, particularly PI3K/Akt and ERK/MAPK pathways, appears critical for proper regulation of invadopodia formation and cancer cell invasion but has not been thoroughly characterized at the molecular level. The potential for targeted disruption of the AFAP1-Src interaction or AFAP1-AS1 function as cancer therapeutics requires further preclinical development and optimization. Finally, the role of AFAP1 in regulating cell-matrix adhesion at the mechanical level, particularly the coupling between AFAP1-organized actin structures and the mechanotransduction signaling through focal adhesion kinase and Src, remains an important area for future investigation that could inform approaches to preventing cancer metastasis and treating fibrotic diseases.

Conclusion

AFAP1 (actin filament-associated protein 1) is a multifunctional adapter protein that plays central roles in organizing the actin cytoskeleton and transducing signals from protein kinase C and integrin receptors to actin-based structures critical for cell adhesion, migration, and invasion. The protein functions through multiple interconnected mechanisms: direct interaction with and activation of c-Src kinase through its N-terminal SH3 binding motif; cross-linking of actin filaments through its C-terminal actin-binding domain; integration of signals from PKCα through PKC-mediated phosphorylation at serine 277; and recruitment of signaling complexes to sites of actin remodeling[1][4][9][12][14][54]. AFAP1 achieves these functions through a modular protein architecture featuring two Pleckstrin Homology domains, Src interaction motifs, and actin-binding regions that collectively enable AFAP1 to serve as a hub for coordinating multiple signaling inputs and translating them into coherent changes in cytoskeletal organization. AFAP1 is required for formation of podosomes (in response to PKC activation) and invadopodia (specialized invasive structures in cancer cells), and regulates the assembly and dynamics of focal adhesions and stress fibers critical for cell adhesion and migration[12][16][17][26][29][41]. In addition to its protein-level functions, the AFAP1 gene locus produces AFAP1-AS1, a long noncoding RNA with oncogenic functions in numerous cancer types that acts primarily as a competing endogenous RNA to sequester microRNAs and modulate gene expression[2][9][14][21][25][36][38].

AFAP1 is broadly expressed across tissues, with particularly prominent expression in tissues with high cellular motility and dynamic adhesion requirements including the nervous system, reproductive tissues, and vascular tissues[23][28][59]. The protein is regulated through multiple mechanisms including post-translational phosphorylation and transcriptional control of both the protein-coding AFAP1 mRNA and the lncRNA AFAP1-AS1. Dysregulation of AFAP1 and AFAP1-AS1 has been implicated in cancer progression and metastasis across numerous cancer types, and genetic variants in the AFAP1 locus have been associated with primary open-angle glaucoma, suggesting that normal AFAP1 function is critical for maintaining actin dynamics in tissues controlling intraocular pressure. Future research should aim to elucidate the three-dimensional structure of AFAP1 in complex with its binding partners, clarify the tissue-specific functions of AFAP1 isoforms, and develop approaches to selectively target AFAP1 function therapeutically with minimal toxicity to normal tissues. The remarkable functional versatility of AFAP1—coupling multiple signaling inputs to coordinate changes in actin filament organization across diverse cellular contexts—exemplifies how multidomain scaffold proteins achieve regulatory specificity through modular domain architecture and selective binding partner interactions.

Citations

1. https://en.wikipedia.org/wiki/AFAP1
2. https://www.medsci.org/v14p1022.htm
3. https://zfin.org/ZDB-GENE-100316-6
4. https://www.ncbi.nlm.nih.gov/gene/60312
5. https://pmc.ncbi.nlm.nih.gov/articles/PMC4302073/
6. https://pmc.ncbi.nlm.nih.gov/articles/PMC3085893/
7. https://pmc.ncbi.nlm.nih.gov/articles/PMC11114525/
8. https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=60312
9. https://maayanlab.cloud/Harmonizome/gene/AFAP1
10. https://www.uniprot.org/uniprotkb/Q8N556/entry
11. https://pmc.ncbi.nlm.nih.gov/articles/PMC11772456/
12. https://www.oncotarget.com/article/16880/text/
13. https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.237
14. https://pubchem.ncbi.nlm.nih.gov/protein/P12931
15. https://www.proteinatlas.org/ENSG00000196526-AFAP1
16. https://www.deciphergenomics.org/gene/afap1/overview/clinical-info
17. https://pmc.ncbi.nlm.nih.gov/articles/PMC9509167/
18. https://pmc.ncbi.nlm.nih.gov/articles/PMC3711196/
19. https://pubmed.ncbi.nlm.nih.gov/31081081/
20. https://www.proteinatlas.org/ENSG00000196526-AFAP1/tissue
21. https://pmc.ncbi.nlm.nih.gov/articles/PMC3085414/
22. https://www.europeanreview.org/wp/wp-content/uploads/3284-3290.pdf
23. https://pmc.ncbi.nlm.nih.gov/articles/PMC1456526/
24. https://pubmed.ncbi.nlm.nih.gov/12058076/
25. https://pmc.ncbi.nlm.nih.gov/articles/PMC4177327/
26. https://www.pnas.org/doi/10.1073/pnas.2202723119
27. https://www.molbiolcell.org/doi/abs/10.1091/mbc.e02-01-0018
28. https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.777849/full
29. https://pmc.ncbi.nlm.nih.gov/articles/PMC5110387/
30. https://pubmed.ncbi.nlm.nih.gov/17520695/
31. https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.681576/full
32. https://pmc.ncbi.nlm.nih.gov/articles/PMC515031/
33. https://pmc.ncbi.nlm.nih.gov/articles/PMC4303145/
34. https://olink.com/assay/explore/oncology/proto-oncogene-tyrosine-protein-kinase-src
35. https://string-db.org/network/9031.ENSGALP00000036444
36. https://www.uniprot.org/uniprotkb/P12931/entry
37. https://stacks.cdc.gov/view/cdc/192171/cdc_192171_DS1.pdf
38. https://www.uniprot.org/uniprotkb/Q90738/entry
39. https://pmc.ncbi.nlm.nih.gov/articles/PMC9835296/
40. https://platform.opentargets.org/target/ENSG00000196526
41. https://pmc.ncbi.nlm.nih.gov/articles/PMC5885413/

AFAP1: Evidence for Signal-Regulated Actin Cross-Linking as a Distinct Molecular Function from Src/PKC Adaptor Activity

Summary

AFAP1 (Actin Filament-Associated Protein 1, also known as AFAP-110) possesses a direct, biochemically demonstrated actin filament cross-linking activity that is mechanistically separable from its well-characterized role as a Src/PKC-associated molecular adaptor. This conclusion is supported by three independent lines of in vitro evidence using purified recombinant protein: (1) low-speed sedimentation assays demonstrating F-actin cross-linking dependent on the C-terminal actin-binding domain (residues 594–637); (2) leucine zipper deletion/mutation experiments showing that disruption of self-association increases cross-linking capacity; and (3) PKC phosphorylation of purified protein increasing cross-linking activity. Crucially, separation-of-function experiments demonstrate that these two activities — actin cross-linking and Src activation — can be dissociated: a c-Fos leucine zipper substitution mutant increases cross-linking without activating cSrc, and dominant-positive RhoA blocks actin reorganization without inhibiting Src activation.

Despite this compelling biochemical evidence, current Gene Ontology and UniProt annotations for human AFAP1 (Q8N556) capture only generic "actin binding" (GO:0003779, IEA) and "molecular adaptor activity" (GO:0060090, IEA), entirely missing the more specific cross-linking function. Neither "actin filament cross-linking activity" nor any signal-regulated qualifier is annotated, even though the supporting biochemical data from the avian ortholog (two key papers: Qian et al. 2002, 2004) meet the standard for experimental evidence codes. A more specific annotation — "signal-regulated actin-filament cross-linking activity" — is justified by the existing literature.

However, important gaps remain. All in vitro cross-linking biochemistry was performed with the chicken (avian) AFAP-110 ortholog; no published study has reconstituted human AFAP1 cross-linking in vitro. No high-resolution structure of AFAP1 (or any fragment) has been solved, leaving the auto-inhibitory PH1–leucine zipper contact and multimerization interface as models inferred from deletion/mutation studies. Finally, no in vivo separation-of-function mutant has been tested that isolates cross-linking from adaptor activity in a physiological context such as lactation or podosome formation.

Key Findings

Finding 1: AFAP1 Has Direct, In Vitro Actin Cross-Linking Activity

The most important evidence distinguishing AFAP1 from a generic adaptor protein is the demonstration that purified recombinant AFAP-110 (rAFAP-110) can directly cross-link actin filaments in vitro. Qian et al. (2002) showed that rAFAP-110 binds F-actin cooperatively through lateral association and cross-links actin filaments in low-speed sedimentation assays — a standard biochemical approach for demonstrating bundling/cross-linking activity (PMID: 12134071). This cross-linking depends on the integrity of the C-terminal actin-binding domain (residues 594–637). Importantly, PKC phosphorylation of the purified protein increased its cross-linking capacity, providing direct evidence that this activity is signal-regulated at the level of the protein itself, not merely through pathway-level effects. As the authors state: "We demonstrate rAFAP-110 has the capability to cross-link actin filaments, and this ability is dependent on the integrity of the carboxy terminal actin binding domain. Deletion of the leucine zipper motif or PKC phosphorylation affected AFAP-110's conformation, which correlated with changes in multimerization and increased the capability of rAFAP-110 to cross-link actin filaments."

Qian et al. (2004) extended these findings by demonstrating that deletion of the leucine zipper motif (Δlzip) or structural disruption through point mutations (L581P) increased the ability of rAFAP-110 to cross-link actin filaments in vitro (PMID: 14755689). Multiple independent leucine zipper mutations all produced the same phenotype — enhanced cross-linking — ruling out mutation-specific artifacts. The paper explicitly states: "AFAP-110 has an intrinsic ability to alter actin filament integrity as an actin filament crosslinking protein. This capability is regulated by a carboxy terminal leucine zipper (Lzip) motif. The Lzip motif facilitates self-association stabilizing the AFAP-110 multimers."

This represents the strongest tier of biochemical evidence: purified recombinant protein assays with defined components, rather than overexpression, co-immunoprecipitation, or localization-based inference.

{{figure:afap1_domain_architecture.png|caption=Domain architecture of AFAP1/AFAP-110 showing the PH1 domain, SH3/SH2 binding motifs, PKC phosphorylation sites, leucine zipper, and C-terminal actin-binding domain. The intramolecular PH1–Lzip contact forms the auto-inhibitory mechanism that regulates cross-linking activity.}}

Finding 2: Cross-Linking Is Auto-Inhibited by PH1–Leucine Zipper Intramolecular Contact

AFAP1's cross-linking activity is not constitutive — it is held in check by an intramolecular auto-inhibitory mechanism. The C-terminal leucine zipper (Lzip) motif contacts the N-terminal PH1 domain, stabilizing a closed conformation that limits multimerization and suppresses cross-linking. This was demonstrated by GST-pulldown experiments showing that the C-terminus/Lzip can directly contact PH1 sequences (PMID: 14755689). The paper describes: "An analysis of opposing binding sites indicated that the carboxy terminus/Lzip motif can contact sequences within the amino terminal pleckstrin homology (PH1) domain indicating an auto-inhibitory mechanism for regulating multimer stability and actin filament crosslinking."

Disruption of this intramolecular contact — whether by Lzip deletion (Δlzip), the L581P point mutation, or c-Fos leucine zipper substitution — releases the auto-inhibition and increases actin cross-linking capacity. This mechanism provides the structural basis for signal-dependent regulation: PKC phosphorylation induces a conformational change that disrupts the PH1–Lzip contact, thereby activating cross-linking activity.

This auto-inhibitory model is consistent with the behavior of other signal-regulated actin cross-linkers (e.g., filamin, α-actinin) where conformational changes gate cross-linking activity, and it distinguishes AFAP1 from constitutive cross-linkers.

Finding 3: Multimerization via Leucine Zipper Is Required for Cross-Linking

Actin filament cross-linking mechanistically requires at least two actin-binding domains to bridge separate filaments, which means AFAP1 must multimerize to cross-link. Qian et al. (1998) demonstrated that AFAP-110 self-associates through its leucine zipper motif, forming multimers detectable by Superose size-exclusion chromatography (PMID: 9619827). The study found that "Superose chromatography demonstrate that AFAP-110 will fractionate as a monomer or multimer, indicating AFAP-110 can be detected in a self-associated form in cell lysates. Co-expression of Src527F resulted in AFAP-110 fractionating with a molecular weight that predicts only a multimeric population."

The relationship between multimerization and cross-linking is nuanced: paradoxically, disrupting the leucine zipper (which destabilizes ordered multimers) increases cross-linking capacity. This suggests that the native leucine zipper constrains multimerization into a specific geometry that auto-inhibits cross-linking, and that disruption allows formation of alternative multimeric assemblies with higher cross-linking activity.

Finding 4: Adaptor Function and Actin Cross-Linking Are Mechanistically Coupled but Separable

This is the central finding for the research question. Multiple lines of evidence demonstrate that AFAP1's adaptor function (Src/PKC binding and activation) and its actin cross-linking activity are linked through shared conformational control but can be experimentally dissociated.

Evidence for coupling:
- Δlzip simultaneously increases cross-linking AND activates cSrc (PMID: 11641786)
- The PKCα → AFAP-110 → cSrc → podosome pathway requires intact AFAP-110 SH3 binding (PMID: 15314167)
- SH3 binding motif mutation of Δlzip prevents both Src activation AND actin filament reorganization

Evidence for separability:
- c-Fos Lzip substitution increases cross-linking but does NOT activate cSrc (PMID: 14755689) — This is the key separation-of-function result. The c-Fos substitution preserves the helical structure (enabling cross-linking) but alters the specific amino acid sequence needed for Src-activating conformational change.
- RhoA(V14) blocks Δlzip actin rosette formation but does NOT inhibit Src activation (PMID: 11641786) — This demonstrates that the actin-reorganizing output can be blocked downstream without affecting Src kinase activation. The paper states: "A point mutation that alters the SH3-binding motif of AFAP-110(Deltalzip) prevents it from activating tyrosine kinases and altering actin filament integrity. In addition, a deletion within a pleckstrin homology (PH) domain of AFAP-110(Deltalzip) will also revert its effects upon actin filaments. Lastly, dominant-positive RhoA(V14) will block the ability of AFAP-110(Deltalzip) from inducing actin filament rosettes, but does not inhibit Src activation."
- In prostate cancer, PKC-binding-deficient AFAP-110 fails to restore adhesion, while Src-binding-deficient AFAP-110 succeeds (PMID: 17885682) — As the authors report: "Reintroduction of avian AFAP-110 or a mutant disabling its interaction with Src restored these properties. However, expression of an AFAP-110 lacking the PKC-interacting domain failed to restore properties of parental cells." This suggests that PKC-mediated conformational regulation (which governs cross-linking) is dominant for cellular phenotype.

{{figure:evidence_classification.png|caption=Classification of evidence for AFAP1 molecular functions. Direct biochemical evidence (highest tier) supports actin cross-linking with purified protein; cellular and genetic evidence supports adaptor function. Separation-of-function experiments demonstrate the two activities are dissociable.}}

Finding 5: Current GO/UniProt Annotations Underrepresent Cross-Linking Function

Human AFAP1 (UniProt Q8N556) carries only two molecular function GO annotations, both assigned by electronic inference (IEA): GO:0003779 "actin binding" and GO:0060090 "molecular adaptor activity." It lacks GO:0051015 "actin filament binding," GO:7770064 "actin-filament cross-linking activity," and GO:0051764 "actin crosslink formation" — despite published in vitro evidence from the avian ortholog.

UniProt free text notes that AFAP1 "Can cross-link actin filaments into both network and bundle structures," but qualifies this as "By similarity" rather than citing the direct chicken biochemical data. Even the chicken entry (Q90738) lacks cross-linking GO terms. For comparison, fascin — an established actin cross-linker — does carry IDA (Inferred from Direct Assay) evidence for GO:0051015 and GO:0003779, showing that such annotations are applied when the evidence supports them.

This represents a significant annotation gap: the most specific and mechanistically informative molecular function of AFAP1 is invisible in standard database queries and gene set enrichment analyses.

Mechanistic Model

Based on the evidence reviewed, the following mechanistic model emerges for AFAP1's dual function:

    AUTO-INHIBITED STATE (Resting)
    ┌─────────────────────────────┐
    │  PH1 ←──contact──→ Lzip     │
    │   │                   │      │
    │  SH3bm             ABD       │
    │  (accessible)   (constrained) │
    └─────────────────────────────┘
              │
      ┌───────────────┼───────────────┐
      ▼               ▼               ▼
PKC phosph.     Lzip mutation     Src binding
      │               │               │
      ▼               ▼               ▼
┌─────────────────────────┐     ┌──────────┐
│   CONFORMATIONAL CHANGE │     │ Adaptor  │
│   PH1–Lzip released     │     │ scaffold │
│   ↓                     │     │ function │
│   Multimerization       │     └──────────┘
│   changes               │
│   ↓                     │
│   Enhanced actin        │
│   cross-linking         │
└────────┬────────────────┘
 │
    ┌────────────┼────────────────┐
    ▼            ▼                ▼
  Actin        cSrc           Downstream
  network    activation*      phenotypes
  remodeling  (requires        (podosomes,
      specific Lzip    invadopodia,
      geometry)        adhesion)

  * c-Fos Lzip substitution → cross-linking YES, Src activation NO
  * RhoA(V14) → actin remodeling NO, Src activation YES

Key insight: The conformational change induced by PKC phosphorylation or Lzip disruption serves as a branching point. Cross-linking activation requires only the release of the PH1–Lzip contact and consequent multimerization changes. Src activation additionally requires specific structural features of the native Lzip sequence (not just any coiled-coil). This explains why some mutations (c-Fos substitution) can activate one output without the other.

The model also explains why PKC-binding-deficient AFAP1 fails to rescue cellular phenotypes even when Src-binding is intact (PMID: 17885682): without PKC-mediated conformational change, neither cross-linking activation nor the subsequent Src activation cascade is initiated. This positions PKC as the upstream master switch, with cross-linking and adaptor functions as two distinct but co-regulated downstream outputs.

Evidence Base

Core Biochemical Papers (Direct Cross-Linking Evidence)

Adaptor/Signaling Papers

Structural/Binding Papers

GWAS/Disease Association Papers

Multiple GWAS studies have identified AFAP1 as a susceptibility locus for primary open-angle glaucoma (POAG), with expression in retinal ganglion cells, trabecular meshwork, and optic nerve (PMID: 25173105, PMID: 29452408, PMID: 41983772, PMID: 40459497). The mechanistic connection between AFAP1's molecular functions and glaucoma pathogenesis remains unexplored — it is unknown whether the POAG association reflects the cross-linking function, the adaptor function, or both.

Assessment of Evidence Quality

{{figure:afap1_evidence_model.png|caption=Comprehensive evidence model showing the relationship between AFAP1's cross-linking activity, adaptor function, and downstream cellular phenotypes, along with key missing experiments needed to fully resolve the functional architecture.}}

Limitations and Knowledge Gaps

Critical Gaps

1. No human AFAP1 in vitro biochemistry. All cross-linking assays used chicken (avian) AFAP-110. The human ortholog (729 aa vs. 635 aa in chicken) has ~60% sequence identity but includes additional sequence that could alter cross-linking properties. The UniProt annotation "By similarity" reflects this gap.

2. No high-resolution structure. No crystal structure, cryo-EM structure, or NMR structure exists for any AFAP1 domain or fragment. The auto-inhibitory PH1–Lzip contact model is inferred entirely from deletion/mutation studies and GST-pulldown experiments. The geometry of the multimer interface, the mechanism of auto-inhibition, and the structural basis for the c-Fos separation-of-function are all unknown at atomic resolution.

3. No in vivo separation-of-function mutants. The c-Fos Lzip substitution (cross-linking YES / Src activation NO) has only been tested in vitro and in overexpression systems. No knock-in mouse or physiological system has been used to test whether cross-linking can drive cellular phenotypes independently of Src activation.

4. Limited quantitative biochemistry. The cross-linking assays are largely qualitative (sedimentation, microscopy). Binding affinities (Kd for F-actin), cross-linking kinetics, and the stoichiometry of the functional multimer have not been determined.

5. POAG mechanism unknown. Despite robust GWAS associations, the molecular mechanism linking AFAP1 to glaucoma is entirely uncharacterized.

Methodological Considerations

• The existing separation-of-function data (c-Fos Lzip, RhoA block) are from overexpression experiments in cell lines, not endogenous protein at physiological levels.
• The AFAP1 knockout mouse shows a lactation phenotype consistent with loss of Src activation at the apical surface, but this does not directly test cross-linking function.
• Many cellular phenotypes attributed to AFAP1 (podosomes, invadopodia, adhesion) could reflect either or both functions, and existing experiments do not distinguish which function drives which phenotype.
• Nearly all AFAP1 literature comes from the Flynn laboratory and a small number of collaborating groups. Independent replication is limited.
• The key biochemical papers are from 2002–2004. No recent studies have revisited the cross-linking function with modern methods (cryo-EM, quantitative biophysics, reconstitution systems).

Proposed Follow-up Experiments

High Priority

1. Reconstitute human AFAP1 cross-linking in vitro. Express and purify recombinant human AFAP1 and test actin cross-linking by low-speed cosedimentation and electron microscopy. This would validate the "By similarity" annotation and enable human-specific mutational analysis.

2. Solve the structure of the auto-inhibited state. Use AlphaFold2 multimer prediction for the AFAP1 homodimer and validate with cross-linking mass spectrometry (XL-MS). Pursue cryo-EM of the AFAP1–F-actin complex to visualize the cross-linking geometry.

3. c-Fos knock-in mouse. Generate an AFAP1 knock-in mouse carrying the c-Fos Lzip substitution (cross-linking competent, Src activation deficient). Compare lactation, podosome formation, and glaucoma-related phenotypes to the full knockout. This is the definitive test of whether cross-linking and adaptor functions are physiologically separable.

4. Quantitative actin cross-linking assays. Measure Kd for F-actin binding by cosedimentation or fluorescence anisotropy. Determine cross-linking kinetics and network rheology (e.g., by reconstituted actin network microrheology) with and without PKC phosphorylation.

Medium Priority

1. POAG mechanism dissection. Express wild-type and separation-of-function AFAP1 mutants in trabecular meshwork cells. Measure effects on actin cytoskeleton organization, cell contractility, and aqueous humor outflow facility.

2. Live-cell imaging of cross-linking dynamics. Use fluorescently tagged AFAP1 (wild-type vs. c-Fos Lzip vs. Δlzip) to track real-time actin network remodeling in response to PKC activation. Combine with FRAP to measure multimer exchange kinetics.

3. Phosphoproteomic mapping. Identify all PKC phosphorylation sites on AFAP1 by mass spectrometry, and determine which sites regulate cross-linking vs. Src binding vs. conformational change.

Lower Priority

1. Cross-linker comparison. Benchmark AFAP1 cross-linking parameters (bundle spacing, network mesh size, filament alignment) against established cross-linkers (fascin, α-actinin, filamin) to determine whether AFAP1 produces architecturally distinct actin networks.

2. AFAP1L1 cross-linking test. Determine whether the paralog AFAP1L1 (which shares domain architecture but interacts with cortactin rather than Src) also possesses actin cross-linking activity. This would reveal whether cross-linking is a conserved family function or specific to AFAP1.

Supported and Refuted Hypotheses

Supported

• AFAP1 has an intrinsic actin cross-linking activity distinct from its adaptor role. Strongly supported by in vitro data with purified recombinant protein (Qian 2002, 2004).
• The cross-linking activity is signal-regulated via PKC phosphorylation. Supported by in vitro phosphorylation experiments (Qian 2002).
• An auto-inhibitory PH1–Lzip intramolecular mechanism controls cross-linking. Supported by binding and mutagenesis data (Qian 2004).
• Cross-linking and Src activation can be mechanistically separated. Supported by c-Fos Lzip mutant and RhoA experiments (Qian 2004; Baisden 2001).

Refuted

• AFAP1 functions only as a generic Src/PKC adaptor. Refuted by the in vitro cross-linking data. The "adaptor only" model is insufficient to explain the full range of AFAP1's biochemical activities.

Untestable with Current Data

• Human AFAP1 has the same cross-linking activity as chicken AFAP-110. Plausible given sequence conservation but not directly tested.
• AFAP1 cross-linking contributes to glaucoma pathophysiology. No functional data connecting these.
• Cellular phenotypes (podosomes, adhesion, invasion) require cross-linking function specifically. These phenotypes could arise from either cross-linking or adaptor activity and current experiments cannot distinguish between them.

Conclusion

The literature supports a more specific molecular function annotation for AFAP1 than the current "actin binding" and "molecular adaptor activity." Specifically, signal-regulated actin-filament cross-linking activity is justified by direct biochemical evidence from purified protein assays, and this activity is demonstrably separable from Src/PKC adaptor function through separation-of-function mutants. The cross-linking is auto-inhibited by an intramolecular PH1–leucine zipper contact and activated by PKC phosphorylation — making it a bona fide signal-regulated enzymatic-like activity rather than a passive scaffolding function.

The current annotation of only "actin binding" (IEA) and "molecular adaptor activity" (IEA) misses the distinguishing feature of AFAP1: that it is a signal-regulated actin cross-linker whose cross-linking activity is controlled by PKC phosphorylation and an auto-inhibitory intramolecular mechanism. This is a more specific and informative molecular function than either "actin binding" or "molecular adaptor" alone.

The field would benefit enormously from reconstitution of human AFAP1 cross-linking, structural determination of the auto-inhibited state, and a c-Fos knock-in mouse to test physiological separability. The GWAS association with primary open-angle glaucoma provides an additional motivation to understand which molecular function of AFAP1 is relevant in disease.

Key PMIDs

OpenScientist prompt: AFAP1 actin cross-linking versus Src/PKC adaptor function

Investigate whether human AFAP1 has evidence for a direct, signal-regulated actin cross-linking or scaffold molecular function that is distinct from its broader role as a Src/PKC-associated molecular adaptor.

Focus on evidence that separates:

• direct actin binding, actin filament cross-linking, and multimerization;
• Src binding or activation and PKC-regulated conformational control;
• cellular adhesion, podosome, invadopodia, and epithelial/lactation phenotypes that may be downstream of adaptor activity rather than direct molecular function.

Please evaluate whether existing literature supports only broad molecular adaptor and actin-binding annotations, or whether a more specific molecular function such as signal-regulated actin cross-linking/scaffold activity is justified. Distinguish direct biochemical or structural evidence from overexpression, localization, and pathway readouts. Include PMIDs and note key missing experiments.